WO2020166469A1 - 情報提供方法、情報提供装置及びプログラム - Google Patents
情報提供方法、情報提供装置及びプログラム Download PDFInfo
- Publication number
- WO2020166469A1 WO2020166469A1 PCT/JP2020/004478 JP2020004478W WO2020166469A1 WO 2020166469 A1 WO2020166469 A1 WO 2020166469A1 JP 2020004478 W JP2020004478 W JP 2020004478W WO 2020166469 A1 WO2020166469 A1 WO 2020166469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- information
- score
- image
- tissue section
- fluorescent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 84
- 238000004458 analytical method Methods 0.000 claims abstract description 52
- 239000000126 substance Substances 0.000 claims description 64
- 239000002105 nanoparticle Substances 0.000 claims description 51
- 230000008569 process Effects 0.000 claims description 28
- 238000010186 staining Methods 0.000 claims description 28
- 238000002073 fluorescence micrograph Methods 0.000 claims description 26
- 239000012128 staining reagent Substances 0.000 claims description 12
- 239000012620 biological material Substances 0.000 claims description 7
- 230000004807 localization Effects 0.000 claims description 4
- 238000012800 visualization Methods 0.000 claims description 4
- 238000000339 bright-field microscopy Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 121
- 210000004027 cell Anatomy 0.000 description 89
- 206010028980 Neoplasm Diseases 0.000 description 55
- 239000013076 target substance Substances 0.000 description 39
- 210000003855 cell nucleus Anatomy 0.000 description 37
- 238000001000 micrograph Methods 0.000 description 32
- 239000007850 fluorescent dye Substances 0.000 description 30
- 238000010827 pathological analysis Methods 0.000 description 29
- 239000002245 particle Substances 0.000 description 28
- 238000012545 processing Methods 0.000 description 28
- 229920005989 resin Polymers 0.000 description 28
- 239000011347 resin Substances 0.000 description 28
- 239000000523 sample Substances 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 239000000975 dye Substances 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 23
- 239000002096 quantum dot Substances 0.000 description 22
- 238000011282 treatment Methods 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- 210000004204 blood vessel Anatomy 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000002865 immune cell Anatomy 0.000 description 18
- 230000000877 morphologic effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000004891 communication Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- -1 Foxp3 Proteins 0.000 description 14
- 238000004364 calculation method Methods 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 125000000524 functional group Chemical group 0.000 description 13
- 108090001008 Avidin Proteins 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 125000003277 amino group Chemical group 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000007654 immersion Methods 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 229960002685 biotin Drugs 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 210000002536 stromal cell Anatomy 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 238000004393 prognosis Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000006087 Silane Coupling Agent Substances 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001215 fluorescent labelling Methods 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
- 102100038078 CD276 antigen Human genes 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- 102100031351 Galectin-9 Human genes 0.000 description 4
- 101710121810 Galectin-9 Proteins 0.000 description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 4
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 4
- 102100034980 ICOS ligand Human genes 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 229920000877 Melamine resin Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000012099 Alexa Fluor family Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000004640 Melamine resin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- JLDSMZIBHYTPPR-UHFFFAOYSA-N Alexa Fluor 405 Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.C12=C3C=4C=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C1=CC=C3C(S(=O)(=O)[O-])=CC=4OCC(=O)N(CC1)CCC1C(=O)ON1C(=O)CCC1=O JLDSMZIBHYTPPR-UHFFFAOYSA-N 0.000 description 2
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 108050000637 N-cadherin Proteins 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium dioxide Chemical compound O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 125000005372 silanol group Chemical group 0.000 description 2
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YMYNYVDHGPDOCK-UHFFFAOYSA-N 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5,6-dicarboxylic acid Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=C1C=C(C(O)=O)C(C(=O)O)=C2 YMYNYVDHGPDOCK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- DCQBZYNUSLHVJC-UHFFFAOYSA-N 3-triethoxysilylpropane-1-thiol Chemical compound CCO[Si](OCC)(OCC)CCCS DCQBZYNUSLHVJC-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012104 Alexa Fluor 500 Substances 0.000 description 1
- 239000012105 Alexa Fluor 514 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012111 Alexa Fluor 610 Substances 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 239000012113 Alexa Fluor 635 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102100029758 Cadherin-4 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 229910000673 Indium arsenide Inorganic materials 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IXQIUDNVFVTQLJ-UHFFFAOYSA-N Naphthofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=C2C=CC2=CC(O)=CC=C21 IXQIUDNVFVTQLJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010086890 R-cadherin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 229910007709 ZnTe Inorganic materials 0.000 description 1
- MBHRHUJRKGNOKX-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)amino]methanol Chemical compound NC1=NC(N)=NC(NCO)=N1 MBHRHUJRKGNOKX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000005370 alkoxysilyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007849 furan resin Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229910021480 group 4 element Inorganic materials 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- RPQDHPTXJYYUPQ-UHFFFAOYSA-N indium arsenide Chemical compound [In]#[As] RPQDHPTXJYYUPQ-UHFFFAOYSA-N 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000012690 ionic polymerization Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- JXUKBNICSRJFAP-UHFFFAOYSA-N triethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CCO[Si](OCC)(OCC)CCCOCC1CO1 JXUKBNICSRJFAP-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052844 willemite Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10024—Color image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10056—Microscopic image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10064—Fluorescence image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30096—Tumor; Lesion
Definitions
- the present invention relates to an information providing method, an information providing device, and a program.
- tissue sections Conventionally, various judgments have been made based on the information obtained from tissue sections.
- a pathologist obtains morphological information and staining information such as a change in size and shape of cell nuclei, a change in pattern as a tissue, and the like by performing microscopic observation by staining a tissue section in a pathological diagnosis, Based on this, the presence or absence of a lesion and the state of the lesion are observed. Further, such information is also used for predicting the prognosis of a patient based on the observation of tissue sections and predicting the drug efficacy in the clinical or pharmaceutical development process.
- Patent Document 1 a tissue slice obtained from a tumor tissue is imaged to obtain a virtual slide image, and the density of cells and/or blood vessels located near the tumor boundary is measured. It has been shown that the prognosis of a patient can be predicted based on the measured density. Further, in Patent Document 2, the number of immune cells on a tissue section obtained from a tumor tissue is counted, and it is shown that there is a correlation between the density of immune cells present in the tumor tissue and the prognosis of the patient. ing.
- Patent Document 1 uses a technique for digitally analyzing a microscope image, and it can be said that the objectivity is secured as compared with the diagnosis by a pathologist or the like.
- the area, structure, and cell type present on the tissue section are comprehensively observed. That is, a pathologist, for example, first evaluates the area of the tumor area on the tissue section, then evaluates the presence or absence of specific structures such as blood vessels and lymph vessels present in the tissue section, and the number thereof, and further determines the number of tumor cells. Then, the observation is performed in the order of determining the distance between the stromal cells and the tumor cells, and the arrangement relationship between them is also used as the determination material.
- the invention described in Patent Document 2 evaluates the density of immune cells, it does not determine the relationship between other cell types, structures, regions, etc., and thus there is room for improvement in evaluation accuracy. ..
- the present invention has been made in view of the above problems, and is information capable of providing objective and highly accurate support information for various determinations performed based on information obtained from a tissue section.
- An object is to provide a providing method, an information providing device, and a program.
- the information providing method for providing support information for supporting a decision based on information obtained from a tissue section, An image acquisition step of acquiring a digitized bright field image of a tissue section stained for bright field observation, Acquiring a plurality of types of information from the bright field image, a score creating step of creating an analysis score by combining the plurality of types of information, An information presentation step of presenting the analysis score as the support information.
- the invention according to claim 2 is the information providing method according to claim 1,
- the image acquisition step a bright-field image of the entire tissue section obtained by capturing an image of the entire tissue section with a virtual microscope slide creating apparatus is acquired.
- the invention according to claim 3 is the information providing method according to claim 1 or 2,
- the score creating step a plurality of types of information relating to at least any two of the region, structure and cell type present in the tissue section are acquired, and an analysis score is created by combining the plurality of types of information and scoring. To do.
- the invention according to claim 4 is the information providing method according to claim 3, In the score creating step, information on the localization relationship among the region, structure and cell type present in the tissue section is acquired.
- the invention according to claim 5 is the information providing method according to claim 3 or 4,
- the tissue section using a staining reagent in which a biological material recognition site is bound to fluorescent substance-assembled nanoparticles in which a plurality of fluorescent substances are accumulated, a specific biological substance present in the tissue section is stained so that fluorescence observation is possible,
- the image acquisition step further, to obtain a digitized fluorescence image of the tissue section
- the score creating step information regarding the presence of the specific biological substance is further acquired from the fluorescence image, and combined with the plurality of types of information to create a scored analysis score.
- the invention according to claim 6 is the information providing method according to any one of claims 1 to 5, A region visualization step of staining a biological substance existing in a specific region on the tissue section with a fluorescent substance so as to be fluorescently observable is provided.
- An information providing device for providing support information for supporting a decision based on information obtained from a tissue section,
- An image acquisition unit for acquiring a digitized bright-field image of a tissue section stained so that bright-field observation is possible, Acquiring a plurality of types of information from the bright field image, a score creating unit that creates an analysis score by combining the plurality of types of information and scored,
- An information presenting unit that presents the analysis score as the support information.
- the program according to claim 8 is To support the judgment based on the information obtained from the tissue section, the computer of the information providing device that provides the support information, An image acquisition unit for acquiring a digitized bright-field image of a tissue section stained for bright-field observation, A score creating unit that acquires a plurality of types of information from the bright field image and creates an analysis score that is a score by combining the plurality of types of information, An information presenting unit that presents the analysis score as the support information, To function as.
- an information providing method capable of providing objective and highly accurate support information for various judgments made based on information obtained from a tissue section. can do.
- Area “Area” refers to an area in which the same structure or cells are present in a certain amount in a collection. Among the regions, the “tumor region” according to the present embodiment refers to a region formed by a certain amount of tumor cells described below, and the “stromal region” is a certain amount of the stromal cells described below. The formed area is shown. 2. Structure “Structure” refers to a structure in which cells are present in a certain amount and are performing some physiological activity. Examples of the structure include blood vessels, lymphatic vessels, secretory glands, and the like. 3. Cell type “Cell type” refers to the smallest unit cell type that has a function and functions by itself.
- the “tumor cell” in the present embodiment refers to a cell that autonomously and excessively proliferates against control in the living body, and includes “cancer cell” that forms a malignant tumor.
- “Stromal cells” broadly refer to cells that form the supporting structure of living tissues, and include immune cells, inflammatory cells, fibroblasts, endothelial cells and the like. It is known that cancer progresses when cancer cells and stromal cells interact closely with each other.
- FIG. 1 shows an example of the overall configuration of a pathological diagnosis support system 100 that executes the information providing method according to this embodiment.
- the pathological diagnosis support system 100 is a system that acquires and analyzes a microscope image of a tissue section stained with a predetermined staining reagent, and outputs support information. Conventionally, based on information related to specific regions, structures, cell types present in tissue slices, information such as expression levels of specific biological substances present in tissue slices, and localization of active ingredients of drugs administered to living organisms. Various judgments such as prediction of drug efficacy of a drug administered to a living body, prediction of prognosis of an observation target, or pathological diagnosis are performed.
- the support information is provided to support the improvement of the accuracy of these judgments.
- the support information can take the form of an analysis score calculated based on information such as a specific region on a tissue section, a structure, the number of existing cell types and arrangement, and the like. It functions as an objective and highly accurate index to support judgment.
- the pathological diagnosis support system 100 is configured by connecting a microscope image acquisition apparatus 1A and an information providing apparatus 2A via a communication network N so that data can be transmitted and received.
- the pathological diagnosis support system 100 is a system in which the microscope image acquisition device 1A and the information providing device 2A are arranged in the vicinity of each other such as in the same building, and the microscope image acquisition device 1A and the information providing device 2A are It may be either a case where the systems are located far away from each other or a case where the systems are located far away from each other.
- the communication network N is not particularly limited, and the connection method may be wired or wireless, but when the microscope image acquisition apparatus 1A and the information providing apparatus 2A are arranged in the vicinity, for example, a LAN (Local Area Network) ), and when the microscope image acquisition apparatus 1A and the information providing apparatus 2A are arranged at remote locations, for example, a WAN (Wide Area Network) such as the Internet is used.
- a LAN Local Area Network
- WAN Wide Area Network
- the microscope image acquisition apparatus 1A is a virtual microscope slide creation apparatus (for example, see Japanese Patent Publication No. 2002-514319) that scans a slide on a slide fixing stage of a microscope to acquire a digital image of the entire tissue section.
- the entire image of the tissue section of (1) is acquired on the display unit at a time so that image data is acquired and transmitted to the information providing device 2A.
- the microscope image acquisition apparatus 1A includes an irradiation unit, an image forming unit, an image pickup unit, a communication I/F, and the like.
- the irradiation unit includes a light source, a filter, and the like, and irradiates the tissue section on the slide mounted on the slide fixing stage with light.
- the image forming means includes an eyepiece lens, an objective lens, and the like, and forms an image of transmitted light, reflected light, or fluorescence emitted from the tissue section on the slide by the irradiated light.
- the imaging unit is a microscope-installed camera that includes a CCD (Charge Coupled Device) sensor and the like, and that captures an image formed on the imaging surface by the imaging unit to generate digital image data of a microscope image.
- the communication I/F transmits the generated digital image data of the microscope image to the information providing device 2A via the communication network N.
- the microscope image acquisition apparatus 1A includes a bright field unit in which an irradiation unit and an imaging unit suitable for bright field observation are combined, and a fluorescence unit in which an irradiation unit and an imaging unit suitable for fluorescence observation are combined.
- the bright field image can be obtained using the former and the fluorescence image can be obtained using the latter.
- the microscope image acquisition apparatus 1A When the microscope image acquisition apparatus 1A is connected to the Internet as the communication network N, the acquired microscope image is stored in a server apparatus on the Internet so that it can be browsed on the information providing apparatus 2A also connected to the Internet. It becomes possible to do. That is, even when the microscope image acquisition device 1A and the information providing device 2A are arranged at points far apart from each other, the user can use the information providing device 2A to display information acquired by the microscope image acquiring device from a remote location. It is possible to use.
- the virtual microscope slide creation device is used as the microscope image acquisition device 1A, but the invention is not limited to this, and a known microscope with a camera may be used. With a camera-equipped microscope, it is possible to acquire a microscope image of a predetermined field of view for a tissue section on a slide placed on a slide fixing stage.
- the information providing device 2A outputs the support information generated by analyzing the microscope image transmitted from the microscope image acquisition device 1A.
- FIG. 2 shows a functional configuration example of the information providing device 2A.
- the information providing device 2A includes a control unit 21, an operation unit 22, a display unit 23, a communication I/F 24, a storage unit 25, and the like, and each unit is connected via a bus 26. There is.
- the control unit 21 includes a CPU (Central Processing Unit), a RAM (Random Access Memory), and the like, executes various processes in cooperation with various programs stored in the storage unit 25, and provides the information providing device 2A. Control the operation of.
- the control unit 21 realizes the functions of an image acquisition unit, a score creation unit, and an information presentation unit in cooperation with a program stored in the storage unit 25.
- the operation unit 22 includes a keyboard having a character input key, a numeric input key, various function keys, and the like, and a pointing device such as a mouse.
- the operation signal of the key pressed by the keyboard and the operation signal by the mouse are provided. And are output to the control unit 21 as input signals.
- the display unit 23 includes a monitor such as a CRT (Cathode Ray Tube) and an LCD (Liquid Crystal Display), and displays various screens according to the instruction of the display signal input from the control unit 21.
- a monitor such as a CRT (Cathode Ray Tube) and an LCD (Liquid Crystal Display)
- LCD Liquid Crystal Display
- the communication I/F 24 is an interface for transmitting/receiving data to/from an external device such as the microscope image acquisition apparatus 1A via the communication network N, and the fluorescence image captured by the microscope image acquisition apparatus 1A is used as information. It functions as a means for inputting to the providing device 2A.
- the storage unit 25 is composed of, for example, an HDD (Hard Disk Drive), a semiconductor non-volatile memory, or the like.
- the storage unit 25 stores various programs and various data as described above.
- the information providing device 2A may include a LAN adapter, a router, and the like, and may be configured to be connected to an external device via the communication network N.
- the information providing method according to the present invention is a method of providing support information for supporting various judgments based on information obtained from tissue sections, such as prediction of drug efficacy of an observation target, prediction of prognosis, or pathological diagnosis.
- the information providing method includes at least 1. 1. a step (image acquisition step) of obtaining a digitized bright field image of a tissue section stained with a staining reagent capable of bright field observation; 2. A step of acquiring a plurality of types of information from the bright-field image and combining the plurality of types of information to create a scored analysis score (score creating step); A step of presenting the analysis score to the user as support information (information presenting step). In addition to the above steps, 4. A step (image acquisition step) of acquiring a digitized fluorescence image of a tissue section stained using the fluorescent substance-assembled nanoparticles, and the information acquired from the bright-field image in the score creation step.
- the accuracy of the support information can be improved by combining the information acquired from the fluorescence image and creating an analysis score that is scored.
- the information providing method according to this embodiment includes steps 1 to 4 described above, and creates an analysis score based on the information obtained from the bright field image and the fluorescence image.
- tissue specimen is a specimen slide on which a tissue section or a cell is placed, which is commonly used when evaluating the expression level of a specific biological substance by immunohistochemical staining. Take the form of.
- a tissue section collected from a tumor tissue is used.
- the method for preparing a tissue specimen is not particularly limited. Generally, for example, a tissue section collected from a subject is fixed with formalin or the like, dehydrated with alcohol, and then treated with xylene to obtain a high-temperature paraffin.
- a tissue sample prepared by immersing in paraffin and embedding in paraffin can be obtained by making a 3-4 ⁇ m section, and the tissue slide is placed on a slide glass and dried to prepare a specimen slide. It can be made.
- sample Preparation Step (2.1.1) Deparaffinization Treatment The tissue section is immersed in a container containing xylene to remove paraffin.
- the temperature is not particularly limited, but it can be performed at room temperature.
- the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, xylene may be replaced during the immersion.
- the temperature is not particularly limited, but it can be performed at room temperature.
- the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, ethanol may be replaced during the immersion.
- the temperature is not particularly limited, but it can be performed at room temperature.
- the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, water may be exchanged during the immersion.
- the target substance is activated according to a known method.
- the activation conditions are not particularly defined, but as the activation liquid, 0.01 M citrate buffer solution (pH 6.0), 1 mM EDTA solution (pH 8.0), 5% urea, 0.1 M Tris-hydrochloric acid buffer solution is used. A liquid or the like can be used.
- the pH condition is such that a signal is generated from the range of pH 2.0 to 13.0 depending on the tissue section to be used and the roughness of the tissue is such that the signal can be evaluated. Usually, it is carried out at pH 6.0 to 8.0, but it is also carried out at pH 3.0 for special tissue sections.
- an autoclave As a heating device, an autoclave, a microwave, a pressure cooker, a water bath, etc. can be used.
- the temperature is not particularly limited, but it can be performed at room temperature.
- the temperature can be 50 to 130° C., and the time can be 5 to 30 minutes.
- the activated section is immersed in a container containing PBS for washing.
- the temperature is not particularly limited, but it can be performed at room temperature.
- the immersion time is preferably 3 minutes or more and 30 minutes or less. If necessary, PBS may be replaced during the immersion.
- the morphological staining step is a step of performing staining for visualization so that the morphology of cells, tissues, organs and the like can be observed in a bright field.
- staining with eosin which stains cytoplasm, stroma, various fibers, erythrocytes, and keratinocytes from red to deep red
- Staining with hematoxylin which stains cell nuclei, lime, cartilage tissue, bacteria, and mucus in blue-blue to pale blue, is also standardly used (the method of performing these two stainings at the same time is hematoxylin-eosin staining).
- the morphological dyeing step can be performed according to a conventional method. For example, in the case of HE staining, a tissue sample is immersed in a Mayer's hematoxylin solution for hematoxylin staining, and then the tissue sample is washed with running water and immersed in an eosin solution for eosin staining.
- the conditions for performing the morphological staining step that is, the temperature and the immersion time for immersing the tissue sample in the staining solution can be appropriately adjusted according to a standard method.
- the fluorescent staining step is a step of performing staining for fluorescent observation of the target substance with the fluorescent substance-assembled nanoparticles.
- immunohistochemical staining is performed in which a solution of an immunostaining agent is placed on the section and reacted with the target substance.
- the solution of the immunostaining agent used in the fluorescent staining step may be prepared in advance before this step.
- the fluorescent dyeing step may be performed after the morphological dyeing step, or may be performed before the morphological dyeing step.
- Target substance means a target substance for immunohistochemical staining using a fluorescent label, mainly for detection or quantification from the viewpoint of pathological diagnosis.
- biological substances such as proteins (antigens) and nucleic acids existing in tissue sections are assumed.
- examples of the target substance include an antibody and a nucleic acid contained in a drug (antibody drug, nucleic acid drug, etc.) administered to a living body.
- the target substance one of the biological substances exemplified below is stained.
- the protein include proteins that are expressed in immune cells and can be used as biomarkers.
- OX40L CD252)
- ICOS CD278
- ICOSL CD275
- 4-1BB CD137
- 4-1BBL CD137L
- 2B4 CD244
- GITR CD357
- B7-H3 CD276)
- LAG-3 LAG-3.
- nucleic acid examples include DNA and RNA-related substances (mRNA, tRNA, rRNA, miRNA, non-coding RNA, etc.) and the like.
- a cancer cell-specific protein is used as a delivery means to cancer cells.
- the drug include a drug that includes an antibody that recognizes, a drug that includes an antibody that targets a factor of a signal transduction pathway related to a factor (protein) targeted by an active ingredient, and the like.
- the antibody contained in these pharmaceuticals is preferably an antibody that specifically recognizes a cancer growth regulator, a metastasis regulator, or a cancer cell-specific protein, and may be a monoclonal antibody or a polyclonal antibody.
- the class or subclass of the antibody is not particularly limited, and examples thereof include IgA, IgG, IgE, IgD, IgM, etc., and examples of the subclass include IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
- the term "antibody” includes not only full-length antibodies, but also antibody fragments such as Fab, F(ab)'2, Fv, scFv and chimeric antibodies (humanized antibodies, etc.), multifunctional antibodies.
- the drug containing a nucleic acid as a component is not particularly limited as long as it is a nucleic acid which is DNA or RNA or an artificial nucleic acid such as PNA, and preferred examples include decoy, antisense, siRNA, miRNA, ribozyme, aptamer and plasmid DNA. Can be mentioned.
- Phosphor-integrated nanoparticles (Phosphor Integrated Dot: PID) is a nano-sized particle that emits fluorescence upon irradiation with excitation light and contains one molecule of the target substance.
- the particles are capable of emitting fluorescence of sufficient intensity to represent each as a bright spot.
- the fluorescent substance-assembled nanoparticles have particles made of an organic substance or an inorganic substance as a matrix, and a plurality of fluorescent substances (for example, fluorescent organic dyes and quantum dots described later) are included therein and/or adsorbed on the surface thereof. These are nano-sized particles having a structured structure, such as fluorescent dye integrated nanoparticles and quantum dot integrated nanoparticles.
- the matrix and the fluorescent substance have substituents or moieties having mutually opposite charges, and electrostatic interaction is exerted.
- fluorescent substance used in the staining reagent for obtaining a fluorescent image examples include fluorescent organic dyes and quantum dots (semiconductor particles). It preferably emits visible to near-infrared light having a wavelength in the range of 400 to 1000 nm when excited by ultraviolet to near-infrared light having a wavelength in the range of 200 to 700 nm.
- fluorescent organic dyes include fluorescein dye molecules, rhodamine dye molecules, Alexa Fluor (Invitrogen) dye molecules, BODIPY (Invitrogen) dye molecules, cascade dye molecules, coumarin dye molecules, and eosin dyes. Examples thereof include molecules, NBD-based dye molecules, pyrene-based dye molecules, Texas Red-based dye molecules and cyanine-based dye molecules.
- Alexa Fluor 532 Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor 780.
- BODIPYFL BODIPYTMR, BODIPY493/503, BODIPY530/550, BODIPY558/568, BODIPY564/570, BODIPY576/589, BODIPY581/591, BODIPY630/650, BODIPY650/665 (above Invitrogen) ), methoxycoumarin, eosin, NBD, pyrene, Cy5, Cy5.5, Cy7 and the like. You may use individually or in mixture of 2 or more types.
- the quantum dots include II-VI group compounds, III-V group compounds, or quantum dots containing group IV elements as components (“II-VI group quantum dots”, “III-V group quantum dots”, “ Also referred to as "Group IV quantum dot”). You may use individually or in mixture of 2 or more types.
- CdSe CdS, CdS, CdTe, ZnSe, ZnS, ZnTe, InP, InN, InAs, InGaP, GaP, GaAs, Si, and Ge, but are not limited thereto.
- a quantum dot having the above-mentioned quantum dot as a core and a shell provided thereon.
- CdSe/ZnS when the core is CdSe and the shell is ZnS, it is expressed as CdSe/ZnS.
- CdSe/ZnS, CdS/ZnS, InP/ZnS, InGaP/ZnS, Si/SiO2, Si/ZnS, Ge/GeO2, Ge/ZnS and the like can be used, but are not limited thereto.
- the quantum dots may be surface-treated with an organic polymer or the like, if necessary.
- CdSe/ZnS having a surface carboxy group manufactured by Invitrogen
- CdSe/ZnS having a surface amino group manufactured by Invitrogen
- the fluorescent substance to be accumulated in the fluorescent substance-assembled nanoparticles in addition to the fluorescent organic dye and the quantum dot as described above, for example, Y2O3, Zn2SiO4, etc. are used as a matrix, and Mn2+, Eu3+, etc. are used as activators.
- a "photophosphor" can be mentioned.
- thermosetting resins such as melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, and furan resin.
- Resins generally classified as thermoplastic resins such as styrene resin, acrylic resin, acrylonitrile resin, AS resin (acrylonitrile-styrene copolymer), ASA resin (acrylonitrile-styrene-methyl acrylate copolymer)
- Other resins such as polylactic acid; polysaccharides can be exemplified.
- examples of the inorganic material in the matrix include silica and glass.
- Quantum dot integrated nanoparticles have a structure in which the quantum dots are encapsulated in the matrix and/or adsorbed on the surface thereof. .. When the quantum dots are encapsulated in the matrix, the quantum dots need only be dispersed inside the matrix, and may or may not be chemically bonded to the matrix itself.
- the fluorescent dye-assembled nanoparticles have a structure in which the fluorescent organic dye is encapsulated in the matrix and/or adsorbed on the surface thereof. Have. When the fluorescent organic dye is included in the matrix, the fluorescent organic dye needs only to be dispersed inside the matrix, and may or may not be chemically bonded to the matrix itself.
- the fluorescent substance-assembled nanoparticles can be produced according to a known method. Specifically, for example, silica-based mother particles, the fluorescent substance-containing silica particles in which the fluorescent substance is encapsulated, quantum dots, fluorescent substances such as fluorescent organic dyes, and silica precursors such as tetraethoxysilane. It can be prepared by dropping a solution in which and are dissolved in a solution in which ethanol and ammonia are dissolved and hydrolyzing the silica precursor.
- the fluorescent substance-collected resin particles having a resin as a base material and a fluorescent substance adsorbed on the surface of the resin particles or encapsulated in the resin particles are prepared by first preparing a solution or a dispersion liquid of the resin particles. It can be prepared by adding a fluorescent substance such as a quantum dot or a fluorescent organic dye thereto and stirring the mixture. Alternatively, the fluorescent substance-collecting resin particles can be prepared by adding the fluorescent substance to the solution of the resin raw material and then proceeding with the polymerization reaction.
- thermosetting resin such as a melamine resin
- a raw material of the resin for example, methylol melamine which is a condensate of melamine and formaldehyde
- a fluorescent organic dye for example, methylol melamine which is a condensate of melamine and formaldehyde
- the fluorescent dye-integrated resin particles can be prepared by heating the reaction mixture, which preferably further contains a surfactant and a polymerization reaction accelerator (such as an acid), and proceeding the polymerization reaction by an emulsion polymerization method.
- the resin raw material and the fluorescent organic dye are combined with the organic fluorescent dye by a covalent bond or the like in advance as the resin raw material monomer.
- the reaction mixture containing a polymerization initiator (benzoyl peroxide, azobisisobutyronitrile, etc.) is heated to allow the polymerization reaction to proceed by a radical polymerization method or an ionic polymerization method.
- a polymerization initiator benzoyl peroxide, azobisisobutyronitrile, etc.
- the average particle size of the fluorescent substance-assembled nanoparticles used in the present embodiment is not particularly limited, but those having a large particle size are difficult to access the antigen and have a small particle size. Since the signal of the fluorescent substance-integrated nanoparticles is buried in the background noise (camera noise or cell autofluorescence), the one having a low brightness value is preferably about 20 to 500 nm.
- the average particle size is obtained by taking an electron micrograph using a scanning electron microscope (SEM), measuring the cross-sectional area of a sufficient number of particles, and defining each measured value as the area of the circle. Sought as.
- the average particle diameter is the arithmetic average of the particle diameters of 1000 particles.
- the coefficient of variation was also a value calculated from the particle size distribution of 1000 particles.
- an antibody that specifically recognizes and binds a protein as a target substance as an antigen can be used.
- the primary antibody may be an antibody fragment or derivative rather than a natural full-length antibody as long as it has an ability to specifically recognize and bind to a specific biological substance (antigen).
- An antibody (IgG) that specifically recognizes and binds to the primary antibody as an antigen can be used as the secondary antibody.
- Both the primary antibody and the secondary antibody may be polyclonal antibodies, but monoclonal antibodies are preferred from the viewpoint of quantitative stability.
- the type of animal (immunized animal) that produces the antibody is not particularly limited, and may be selected from mice, rats, guinea pigs, rabbits, goats, sheep and the like as in the past.
- Immunostaining agent As an immunostaining agent, a labeled antibody obtained by directly or indirectly binding an antibody capable of directly or indirectly binding to a target substance and a labeling substance is suitable. It is generated by being dispersed in a medium.
- the primary antibody and the fluorescent substance-incorporated nanoparticles used indirectly that is, the antigen-antibody reaction and the avidin-biotin reaction. It is preferable to use a complex that is linked by a bond other than a covalent bond, but is not limited thereto.
- an immunostaining agent in which an antibody and fluorescent nanoparticles are indirectly linked, [primary antibody against target substance]...[antibody against primary antibody (secondary antibody)] to [fluorescent nanoparticle (nanoparticles containing fluorescent substance)] ]
- “...” represents that the compound is bound by an antigen-antibody reaction, and the form of the bond represented by “to” is not particularly limited, and examples thereof include covalent bond, ionic bond, hydrogen bond, coordinate bond, and physical bond. Adsorption or chemisorption may be mentioned, and a linker molecule may be used if necessary.
- the secondary antibody-fluorescent substance-assembled nanoparticle conjugate can be prepared, for example, by using a silane coupling agent which is a compound widely used for binding an inorganic substance and an organic substance.
- This silane coupling agent is a compound having an alkoxysilyl group that gives a silanol group by hydrolysis at one end of the molecule, and a carboxyl group, an amino group, an epoxy group, a functional group such as an aldehyde group at the other end, It binds to an inorganic substance through the oxygen atom of the silanol group.
- silane coupling agent having a polyethylene glycol chain for example, PEG-silaneno.SIM6492.7 manufactured by Gelest Co.
- silane coupling agent you may use 2 or more types together.
- a known method can be used for the reaction procedure between the fluorescent substance-assembled nanoparticles and the silane coupling agent.
- silica nanoparticles encapsulating the obtained fluorescent substance are dispersed in pure water, aminolopyrtriethoxysilane is added, and the mixture is reacted at room temperature for 12 hours.
- silica nanoparticles containing a fluorescent substance whose surface is modified with an aminopropyl group can be obtained by centrifugation or filtration.
- the antibody can be bonded to the silica nanoparticles encapsulating the fluorescent substance through an amide bond.
- a condensing agent such as EDC (1-Ethyl-3-[3-Dimethylaminopropyl]carbodiimide Hydrochloride: manufactured by Pierce) can be used.
- a linker compound having a site capable of directly binding to silica nanoparticles encapsulating a fluorescent substance modified with an organic molecule and a site capable of binding to a molecular target substance can be used.
- sulfo-SMCC Sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate: having a site selectively reacting with an amino group and a site selectively reacting with a mercapto group: manufactured by Pierce ) Is used, an amino group of silica nanoparticles encapsulating a fluorescent substance modified with aminopropyltriethoxysilane and the mercapto group in the antibody are combined to obtain a silica nanoparticle encapsulating the fluorescent substance to which the antibody is bound.
- sulfo-SMCC Sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate: having
- the fluorescent material is either a fluorescent organic dye or a quantum dot. Similar procedures can be applied even in cases. That is, by impregnating a polystyrene nanoparticle having a functional group such as an amino group with a quantum dot or a fluorescent organic dye, a fluorescent substance-encapsulated polystyrene particle having a functional group can be obtained, and thereafter by using EDC or sulfo-SMCC. Thus, fluorescent substance-collected polystyrene particles to which the antibody is bound are formed.
- an immunostaining agent in which an antibody and fluorescent nanoparticles are indirectly linked, [primary antibody against target substance]... [antibody against primary antibody (secondary antibody)]-[biotin]/[avidin]-[ Fluorophore (nanoparticles with fluorescent substance)] (here, "! indicates that they are bound by an antigen-antibody reaction, and "-" is bound by a covalent bond, which may optionally be via a linker molecule. , And "/" means that they are bound by the avidin/biotin reaction.), which is a complex composed of three molecules.
- the secondary antibody-biotin conjugate uses, for example, a commercially available biotin-labeling reagent (kit) based on a known method capable of binding biotin to a desired antibody (protein). Then, it can be manufactured. If a biotin-modified secondary antibody having biotin bound to a desired antibody in advance is commercially available, it may be used.
- a fluorescent substance-assembled nanoparticle-avidin conjugate (avidin-modified fluorophore) is also produced based on a known method capable of binding avidin to a fluorophore, for example, using a commercially available avidin labeling reagent (kit). can do.
- avidin may be an improved type such as streptavidin or neutravidin, which has a higher binding force with biotin than avidin.
- a specific example of the method for producing the fluorescent substance-assembled nanoparticle-avidin conjugate is as follows.
- a linker molecule such as PEG having a functional group of the resin and a functional group of avidin (protein) at both ends of the molecule, if necessary.
- a linker molecule such as PEG having a functional group of the resin and a functional group of avidin (protein) at both ends of the molecule, if necessary.
- a linker molecule such as PEG having a functional group of the resin and a functional group of avidin (protein) at both ends of the molecule, if necessary.
- a linker molecule such as PEG having a functional group of the resin and a functional group of avidin (protein) at both ends of the molecule, if necessary.
- a linker molecule such as PEG having a functional group of the resin and a functional group of avidin (protein) at both ends of the molecule, if necessary.
- a linker molecule such as PEG having
- a desired functional group can be introduced by surface modification with a silane coupling agent.
- a silane coupling agent For example, if aminopropyltrimethoxysilane is used, an amino group is introduced. be able to.
- a thiol group can be introduced by reacting N-succinimidyl S-acetylthioacetate (SATA) with the amino group of avidin.
- the conditions for performing the fluorescent staining step are appropriately adjusted according to the conventional immunohistochemical staining method so that an appropriate signal can be obtained. can do.
- the temperature is not particularly limited, but it can be performed at room temperature.
- the reaction time is preferably 30 minutes or more and 24 hours or less.
- a known blocking agent such as BSA-containing PBS or a surfactant such as Tween 20 dropwise.
- the immunostaining agent is a complex of [primary antibody (probe)]...[secondary antibody]-[biotin]/[avidin]-[fluorescent nanoparticles (fluorescent substance-accumulated nanoparticles, etc.)]
- Primary antibody primary antibody
- secondary antibody secondary antibody-biotin conjugate
- present invention A treatment (fluorescence labeling treatment) of immersing a tissue section, which is a tissue specimen, in a solution of avidin-fluorescent nanoparticles dispersed in a diluent for fluorescent nanoparticles may be performed.
- tissue specimen that has undergone the morphological staining step and the fluorescent staining step is preferably subjected to treatments such as immobilization/dehydration, clearing, and encapsulation so as to be suitable for observation.
- the immobilization/dehydration treatment may be performed by immersing the tissue sample in a fixation treatment liquid (a cross-linking agent such as formalin, paraformaldehyde, glutaraldehyde, acetone, ethanol and methanol).
- the clearing treatment may be carried out by immersing the tissue sample, which has been fixed and dehydrated, in a clearing solution (xylene, etc.).
- the encapsulation treatment may be performed by immersing the tissue sample after the clearing treatment in the encapsulation liquid.
- the conditions for performing these treatments, such as the temperature and the immersion time for immersing the tissue specimen in a predetermined treatment solution may be appropriately adjusted according to the conventional immunostaining method so that an appropriate signal is obtained. it can.
- the microscope image acquisition apparatus 1A is set to a bright field unit and then set to a desired magnification, and the bright field image of the entire tissue specimen stained in the morphological staining step is observed. ⁇ Take a picture.
- the microscope image acquisition apparatus 1A is set to a fluorescent unit, and the tissue specimen is irradiated with excitation light corresponding to each fluorescent substance that fluorescently labels the target substance used in the fluorescent staining step, and the fluorescent substance is emitted from these fluorescent substances. Observe and take a fluorescence image of the entire tissue sample by fluorescence.
- Score Creation Step First, a plurality of types of information such as a region, structure, and cell type in the bright field image are acquired, and each piece of information is combined to calculate a scored morphological score.
- Examples of software that can be used for image processing and scoring include “ImageJ” (open source).
- the information regarding the presence of the target substance in the fluorescence image is acquired and scored to obtain the biological substance score.
- the information on the presence of the target substance includes information on the amount of the target substance (protein, nucleic acid, antibody contained in a drug, etc.) present in a cell, and the intracellular localization of the target substance. That is, image processing is executed in the information providing device 2A for a fluorescent image captured with respect to the target substance, a fluorescent label signal such as a fluorescent bright spot corresponding to the target substance is extracted, and the coordinates of each bright spot are specified, or By measuring these numbers, the abundance and subcellular localization of the target substance are quantified and scored.
- the biological substance score can be calculated for each of a plurality of types of target substances stained.
- Software such as the above-mentioned "ImageJ” (open source) can also be used for image processing and expression analysis. That is, it is possible to quickly and semi-automatically perform a process of extracting bright points having a predetermined wavelength (color) from the fluorescence image and measuring the number of bright points having a predetermined brightness or higher.
- the final analysis score is created by summing the morphological score calculated in the bright field image and the biological substance score calculated in the fluorescent image.
- the pathological diagnosis support system 100 may include a step of performing fluorescent staining for distinguishing between the tumor region and the stromal region, if necessary. That is, for example, by fluorescently labeling a substance that is often present in the stromal region and performing fluorescence observation, the stromal region where fluorescence is observed and the tumor region where fluorescence is not observed or a weak tendency is observed It becomes possible for the user to confirm the boundary of the above by fluorescence observation. This can support the discrimination between the tumor region and the stromal region based on the bright field image. Specifically, the following dyeing is effective.
- the fluorescent substance used for the fluorescent label is not limited to the fluorescent substance-assembled nanoparticles, and even if a single fluorescent dye is used, the tumor region and the stromal region can be sufficiently distinguished. Specifically, it can be dyed by the same procedure as the above-mentioned "(2.3) Fluorescent dyeing step”. Further, the fluorescent staining of the cytokine can be performed at the same time as the fluorescent staining of the target substance in the above “(2.3) Fluorescent staining step”. However, it is desirable to use fluorescent substances having different fluorescence wavelengths from the fluorescent substance-assembled nanoparticles labeled with the target substance. Examples of cytokines include IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-18, IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , TNF, TGF-. ⁇ is mentioned.
- protein in immune cells refers to a protein that is specifically expressed in immune cells, and fluorescent labeling of the tumor region and stromal region can also be performed by fluorescently labeling the protein. Can be clearly identified by. That is, since the fluorescent brightness based on the immune cells in the stromal region is significantly larger than the fluorescent brightness based on the immune cells in the tumor region, the boundary between the regions can be visually recognized from the difference in brightness.
- an antibody that specifically recognizes and binds to a protein in an immune cell as an antigen is used, and a tissue specimen is stained with an immunostaining agent labeled with the antibody.
- the fluorescent substance for fluorescent labeling is not limited to the fluorescent substance-assembled nanoparticles, and a single fluorescent dye can sufficiently distinguish the tumor region and the stromal region.
- the staining can be performed by the same procedure as the above-mentioned “(2.3) Fluorescent staining step”.
- proteins in immune cells include PD-1, CTLA-4, TIM3, Foxp3, CD3, CD4, CD8, CD25, CD27, CD28, CD70, CD40, CD40L, CD80, CD86, CD160, CD57, CD226, CD112. , CD155, OX40 (CD134), OX40L (CD252), ICOS (CD278), ICOSL (CD275), 4-1BB (CD137), 4-1BBL (CD137L), 2B4 (CD244), GITR (CD357), B7-H3.
- CD276 CD276
- LAG-3 CD223)
- BTLA CD272
- HVEM CD270
- GITRL Galectin-9
- B7-H4 B7-H5
- PD-L2 KLRG-1
- E- E-.
- Cadherin N-Cadherin, R-Cadherin and IDO
- TDO TDO
- CSF-1R HDAC
- CXCR4 FLT-3
- TIGIT TIGIT
- ⁇ Operation of pathological diagnosis support system 100 an operation of acquiring and analyzing the fluorescence image and the bright field image described above will be described.
- a tissue sample stained by using a staining reagent containing a fluorescent substance-accumulated nanoparticle in which any substance selected from proteins expressed in immune cells is selected as a target substance and a biological substance recognition site that recognizes the target substance is bound An example will be described in which the target is an observation target.
- the operator uses two types of staining reagents, an HE staining reagent and a staining reagent that uses fluorescent substance-accumulated nanoparticles that bind to a biological substance recognition site that recognizes a target substance as a fluorescent labeling material, to make a tissue sample. Stain. Then, in the microscope image acquisition device 1A, the bright field image and the fluorescence image are acquired by the procedure of (a1) to (a5). (A1) The operator mounts the tissue sample stained with the HE staining reagent and the staining reagent containing the fluorescent substance-assembled nanoparticles on the slide, and installs the slide on the slide fixing stage of the microscope image acquisition apparatus 1A. ..
- the bright field unit is set, and the photographing magnification and focus are adjusted.
- the imaging unit captures an image of the entire tissue sample to generate image data of a bright-field image, and the image data is transmitted to the information providing device 2A.
- A4) Change the unit to a fluorescent unit.
- A5) The entire tissue sample is imaged by the imaging means without changing the field of view and the imaging magnification to generate image data of the fluorescence image, and the image data is transmitted to the information providing device 2A.
- FIG. 3 shows a flowchart of processing in the information providing device 2A. The processing shown in FIG. 3 is executed by the cooperation of the control unit 21 and the program stored in the storage unit 25.
- step S2 shows a detailed flow of the processing in step S2.
- the process of step S2 is executed in cooperation with the control unit 21 and the program stored in the storage unit 25.
- step S2 the cell type is first identified (step S21).
- FIG. 5 shows a detailed flow of the process in step S21.
- the process of step S21 is executed by the cooperation of the control unit 21 and the program stored in the storage unit 25.
- step S21 the cell nucleus is first extracted (step S211). Specifically, first, the bright-field image is converted into a monochrome image, threshold processing is performed on the monochrome image using a predetermined threshold, and the value of each pixel is binarized. Further, noise processing is performed by performing closing processing and opening processing. After the noise processing, an image (cell nucleus image) in which cell nuclei are extracted is obtained. Next, the image after noise processing is subjected to labeling processing, and a label is given to each of the extracted cell nuclei.
- the labeling process is a process of identifying an object in an image by giving the same label (number) to connected pixels. By labeling processing, each cell nucleus can be identified and labeled from the image after noise processing.
- the cell itself may be extracted in addition to the method of extracting the cell nucleus. In this case, an image in which cells are extracted is acquired after the noise processing, and each cell is labeled by the labeling processing.
- the cell feature amount is calculated (step S212). Specifically, for all the cell nuclei in the cell nucleus image extracted in step S211, from the cell nucleus image, the area A of the cell nucleus, the average concentration B of the cell nucleus, the pixel brightness variation ( ⁇ value) C in the cell nucleus, and the circularity of the cell nucleus. Cell characteristic quantities such as D and flattening ratio E of the cell nucleus are calculated. For the area A of the cell nucleus, the size of the pixel is calculated by measuring the reference length corresponding to the cell nucleus image in advance, and the number of pixels in each cell nucleus extracted in step 211 is integrated. Thus, the area A of the cell nucleus is determined.
- the average concentration B of cells is determined by obtaining the luminance signal value converted into the gray scale of each pixel in the cell nucleus and calculating the average value.
- the pixel brightness variation C is determined by calculating the standard deviation of the brightness signal value of each pixel in the cell nucleus.
- the circularity D and flattening ratio E of the cell nucleus are determined by applying the constant values obtained from the cell nucleus image to the following equations (d) and (e) for each cell nucleus extracted in step 211.
- threshold processing of the cell feature amount is executed based on the calculated cell feature amount (step S213).
- thresholds for distinguishing between tumor cells and normal cells are set, and all the cell nuclei on the cell nucleus image are subjected to these threshold processings to obtain tumor cells or normal cells. Specify as.
- threshold processing for identifying cell types such as immune cells, inflammatory cells, fibroblasts, and endothelial cells in the stromal region may be performed.
- various cell types can be specified by setting an arbitrary threshold value according to the cell type to be identified.
- the above-mentioned factors A to E of the cell feature amount are examples, and another factor different from the above may be used as the factor of the cell feature amount.
- the size and shape of cells, the position and size of cell nuclei, changes in size and shape and mitotic figures, the presence or absence of cytoplasm color and mucus production, and cell nucleus/cytoplasm Area ratio etc. are observed.
- Such an item to be noticed at the time of actual pathological diagnosis may be extracted as a cell feature amount and used for specifying the cell type.
- step S22 the structures of blood vessels, lymph vessels, secretory glands, etc. are identified (step S22).
- step S22 for example, a structure formed by a fixed amount of cells is extracted from the cell nucleus image. Then, from each of the extracted structures, the feature amount such as the area of the structure, the average luminance, the luminance variation, the flatness, and the circularity is calculated, and the blood vessels, lymphatic vessels, secretory glands, etc. are calculated based on the feature amount. Identify.
- step S23 a tumor region in which a certain amount of tumor cells are present and a stromal region in which a certain amount of stromal cells are present is identified.
- step S23 for example, when a set of cells (cell nuclei) identified as tumor cells on the cell nucleus image in step S21 occupies a predetermined area or more, the set of tumor cells is identified as a tumor region. be able to.
- the set of cells (cell nuclei) identified as stromal cells in step S21 occupies a predetermined area or more, the set of stromal cells can be identified as a stromal region.
- the process of step S23 completes the specification of the score calculation target.
- the process of specifying the score calculation target in steps S21 to S23 described above is basically automatically performed in cooperation with the programs stored in the control unit 21 and the storage unit 25. May be accompanied by auxiliary work by a user such as a pathologist.
- the auxiliary work by the user is, for example, in the area specifying process of step S21, the user specifies a specific bright field image on the bright field image displayed on the display unit 23 of the information providing apparatus 2A.
- the operation includes selecting an area by enclosing it with a closed figure such as a polygon or a free curve using the operation unit 22, and defining each selection location such as "tumor area” or "stromal area".
- step S22 and the cell type specifying process of step S23 also include operations of selecting and defining on the bright field image by the user. Further, in the threshold processing of the cell feature amount in step S233, for example, the threshold values of the cell feature amount are adjusted stepwise with respect to the program stored in the storage unit 25 to visually confirm the specified cell type, etc. including.
- the process of specifying the score calculation target in steps S21 to S23 may be automatically performed using the image recognition technique trained by machine learning in addition to the above method. That is, these items in the input brightfield image are learned by learning the region, structure, and cell type that appear in the brightfield image using a method such as neural network, random forest, or SVM (Support Vector Machine). Can be specified automatically.
- a method such as neural network, random forest, or SVM (Support Vector Machine).
- step S3 score creating step.
- FIG. 6 shows a detailed flow of the process in step S3.
- the process of step S24 is executed by the cooperation of the control unit 21 and the program stored in the storage unit 25.
- a score based on the area is calculated (step S31).
- the region-based score is a score of information obtained from various regions such as a tumor region and an interstitial region existing on a tissue section. Since the size of the tumor area is associated with the malignancy of cancer, for example, the proportion of the tumor area in the entire area of the imaged tissue section, or the tumor area and the stromal area in the entire area It is effective to score the ratio of the area, the ratio of the area of the stromal region to the area of the tumor region, and the like.
- the structure-based score is a score of information obtained from various structures such as blood vessels, lymphatic vessels, and secretory vessels existing on a tissue section. Since it is known that the density of blood vessels serves as an index for evaluating the malignancy of cancer, for example, the presence or absence of the structure related to the malignancy of cancer on the tissue section, the density or the number of appearances is scored. Is effective.
- a score based on the cell type is calculated (step S33).
- the score based on the cell type is a score obtained from information obtained from cell types such as tumor cells and stromal cells present on the tissue section. For example, the number of cancer cells and normal cells present on the tissue section may be scored. Moreover, the distance between different cell types such as the density of these cancer cells on the tissue section, the distance between the cancer cells in the tumor area and the immune cells in the stromal area, and the distance between the cancer cells in the tumor area.
- Various information that is noted in pathological diagnosis may be scored, such as the distance between a specific cell output and a specific structure, such as the distance to a blood vessel in the quality region.
- the calculation of the morphological score is completed by the process of step S33, and the process returns to FIG.
- each score may be weighted according to the purpose, or the score subtotal may be calculated at any stage and the subtotal may be weighted.
- the calculation method of the region score, the structure score, and the cell type score described above is an example, and the present invention is not limited to this.
- step S5 when the fluorescence image from the microscope image acquisition apparatus 1A is input by the communication I/F 24 (step S4: image acquisition step), fluorescence bright spots are extracted from the fluorescence image (step S5).
- step S5 first, the R component is extracted from the fluorescence image, and the image from which the R component is extracted is subjected to Tophat conversion.
- the Tophat transform is a process of subtracting the value of the corresponding pixel of the image obtained by applying the minimum value filter and the maximum value filter to the input image in this order from the value of each pixel of the input image.
- the minimum value filter replaces the value of the target pixel with the minimum value of pixels (for example, 3 ⁇ 3 pixels) in the vicinity of the target pixel.
- the maximum value filter replaces the value of the target pixel with the maximum value of the pixels (for example, 3 ⁇ 3 pixels) in the vicinity of the target pixel.
- the Tophat transform By the Tophat transform, small protrusions (areas having higher brightness than neighboring pixels) on the grayscale profile can be extracted. As a result, a fluorescent bright spot candidate image can be obtained.
- noise removal is performed from the fluorescent bright spot candidate image to obtain an image (fluorescent bright spot image) in which the fluorescent bright spots are extracted, and the noise-removed image is subjected to labeling processing to extract the extracted fluorescent fluorescence. A label is assigned to each bright spot.
- step S6 score creating step.
- FIG. 7 shows a detailed flow of the processing in step S6.
- the process of step S6 is executed by the cooperation of the control unit 21 and the program stored in the storage unit 25.
- step S6 first, the images of the bright field image and the fluorescent image are aligned based on the information source commonly detected in the bright field image and the fluorescent image (step S61).
- the bright field image used for the alignment is the cell nucleus image obtained in step S2
- the fluorescence image used for the alignment is the fluorescent bright spot image obtained in step S5.
- the information source commonly detected in the bright field image and the fluorescent image information recognizable in both the bright field image and the fluorescent image is used, and in this embodiment, staining information of eosin, which is a staining material for the tissue section, is used. Is used.
- image feature amounts such as contrast information, edge information, and contour information that characterize the images in the bright field image and the fluorescence image are calculated.
- the contrast information, the edge information, and the contour information in each image are calculated from the eosin staining information of each of the bright field image and the fluorescence image. Then, the information between these images is compared with each other, and the common points thereof are matched with each other, whereby the bright field image and the fluorescence image are aligned.
- step S62 the presence of the target substance in each cell is determined.
- a determination is made (step S62). Specifically, for example, in a state in which the bright field image and the fluorescent image are superimposed, the number of fluorescent bright spots in the portion corresponding to the cell specified in step S23 is calculated. Further, in addition to the number of fluorescent bright spots, a luminance value may be calculated for each bright spot region, and a luminance integrated value obtained by summing the luminance values of all the bright spot regions in the fluorescent image may be calculated.
- a score according to the existence status is calculated (step S63).
- the score according to the state of presence is a score calculated according to the amount of the target substance present per cell, the intracellular localization, and the like.
- the processes of step S5 and step S6 are performed for each target substance, and a biological substance score for each target substance can be obtained.
- the calculation of the biological material score is completed by step S63.
- step S7 score creation step.
- the calculation of the analysis score is performed by adding the morphological score calculated in step S3 and the biological substance score calculated in step S6.
- arbitrary weighting may be performed so that the support information desired by the user can be obtained.
- step S8 information presenting step
- the user can confirm the analysis score presented as the support information by the information providing device 2A.
- the mode of presenting the analysis score is not particularly limited, and the analysis score may be presented in the state of only numerical values, or the analysis score (morphology score and biometric image may be displayed on the bright field image and the fluorescence image. The substance score may be displayed).
- the analysis score and the image are displayed in association with each other, it is easy to visually recognize the relationship between the analysis score and the state of the tissue section, which is highly convenient for the user. With the above, the processing in the information providing device 2A is completed.
- a plurality of types of information are acquired from the digitized bright-field image of the tissue section, and the analysis score is created by combining these pieces of information. , It is presented to the user as support information.
- the analysis score is created by combining these pieces of information.
- not only single information for example, the number of tumor cells
- multiple types of information for example, the number of tumor cells and the number of immune cells
- an analysis score that comprehensively evaluates the tissue section is provided by adding a plurality of types of information.
- the analysis score functions as a highly accurate index in various judgments
- the user can perform pathological diagnosis and the like based on the value of the analysis score, and the user can analyze the analysis score displayed on the information providing device 2A and the organization itself.
- the results By comparing the results with the results of pathological diagnosis and the like made by observing the slices, it is possible to confirm the accuracy of the own judgment.
- objective information can be provided as compared with the subjective judgment by a pathologist or the like, and a pathological diagnosis or the like can be performed by the information providing method according to the present embodiment.
- Various judgments are supported, and accuracy can be improved.
- the analysis score can be created by combining information obtained from regions, structures, and cell types. Similar to a pathological diagnosis by an actual pathologist, since comprehensive evaluation is performed based on these relationships, highly accurate support information can be provided. Furthermore, the localization relationship between regions, structures, and cell types, such as the distance between cancer cells in the tumor region and immune cells in the stromal region, the distance between cancer cells and specific structures such as blood vessels, etc. By creating an analysis score using such information, more reliable support information can be provided. In addition, it is possible to present the information desired by the user as a score by setting a score and an item to be scored according to the purpose, based on scoring each of the region, structure, and cell type.
- the analysis score associated with the amount of the biological substance can be used as a new index in pathological diagnosis and the like.
- the fluorescent dye of the target substance is used, but the fluorescent dyeing step can be omitted.
- the present invention aims to support various judgments by a pathologist or the like by automatically scoring and presenting information obtained from a pathological section, which is based on a bright field image. By using a score that combines multiple types of information (information related to regions, structures, and cell types) that is obtained, it is possible to obtain the result of evaluating a pathological section by a method close to the criteria used by a pathologist or the like to actually make a determination. Therefore, the purpose can be sufficiently achieved.
- Patent Document 1 and Patent Document 2 it is not always necessary to fluorescently stain a biological substance, and an analysis score can be created only by the morphological staining process, and therefore, it is possible to perform an analysis score between slides for each staining. Variation and trouble can be omitted.
- FIG. 8A is a bright-field image 200 obtained by photographing a tissue sample obtained by subjecting a tissue section collected from a subject to HE staining with a bright-field unit of the microscope image acquisition apparatus 1A.
- a tumor region 210 and a stromal region 220 are present on the bright field image 200, and a blood vessel 230 is present in the stromal region 220.
- the target substance HER2
- the fluorescent unit of the microscope image acquisition apparatus 1A is used to identify the same as the bright field image 200. A fluorescence image of the field of view was acquired.
- FIG. 8B is a flowchart showing an analysis score calculation procedure in which information used for scoring is set and score weighting is defined so that the support information desired by the user is output.
- the method of calculating the analysis score according to the flow shown in FIG. 8B will be described by taking the tissue sample shown in FIG. 8A as an example.
- the area area is scored (step S101).
- a value N1 is calculated by scoring the ratio of the area of the tumor region 210 and the stromal region 220 to the area of the entire tissue sample, and N1 is calculated as (area of the tumor region 210 and stromal region 220/
- the value obtained by the formula of the area of the bright field image 200) is a standardized value.
- the presence or absence of the structure is scored (step S102).
- N2 20 when blood vessels are present
- N2 0 when no blood vessels are present.
- N2 20 was obtained because the blood vessel 230 was observed in the interstitial region 220.
- N1 and N2 are weighted based on the number of appearances of the structure (step S103).
- the number of cell types is scored (step S104).
- the cell type density is scored (step S105).
- N4 and N5 are weighted based on the intercellular distance (step S106).
- N6 (N4+N5) ⁇ 2.
- N6 (N4+N5) ⁇ 1.
- the biological substance score N7 is calculated (step S108).
- the analysis scores N are acquired by summing up the scores calculated as described above (step S108).
- N N3+N6+N7.
- the user can judge the malignancy of the cancer of the subject by referring to the analysis score. In this way, the analysis score can be used as various indicators in pathological diagnosis and the like.
- an HDD, a semiconductor nonvolatile memory, or the like is used as a computer-readable medium of the program according to the present invention, but the invention is not limited to this example.
- a portable recording medium such as a CD-ROM can be applied.
- a carrier wave is also applied as a medium for providing the data of the program according to the present invention via a communication line.
- the present invention is used for an information providing method, an information providing apparatus, and a program capable of providing objective and highly accurate support information for various judgments made based on information obtained from a tissue section. You can
- Microscope image acquisition device 1A
- Information provision device 21 Control unit (image acquisition unit, score calculation unit, information presentation unit) 22 Operation unit 23
- Display unit 24 Communication I/F 25 Storage N Communication network
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Radiology & Medical Imaging (AREA)
- Quality & Reliability (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
組織切片から得られる情報に基づく判断を支援するための、支援情報を提供する情報提供方法であって、
明視野観察可能に染色された組織切片の、デジタル化された明視野画像を取得する画像取得工程と、
前記明視野画像から複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成するスコア作成工程と、
前記解析スコアを、前記支援情報として提示する情報提示工程と、を備える。
前記画像取得工程において、前記組織切片の全体を撮像可能なバーチャル顕微鏡スライド作成装置で撮像することによって得られた、前記組織切片の全体の明視野画像を取得する。
前記スコア作成工程において、前記組織切片に存在する領域、構造及び細胞種のうち少なくともいずれか二つに係る複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成する。
前記スコア作成工程において、前記組織切片に存在する領域、構造及び細胞種の間の局在の関係性に係る情報を取得する。
前記組織切片は、蛍光物質を複数集積した蛍光物質集積ナノ粒子に生体物質認識部位を結合した染色試薬を用いて、当該組織切片に存在する特定の生体物質が蛍光観察可能に染色され、
前記画像取得工程において、さらに、前記組織切片のデジタル化された蛍光画像を取得し、
前記スコア作成工程において、さらに、前記蛍光画像から前記特定の生体物質の存在に係る情報を取得し、前記複数種の情報と組み合わせてスコア化した解析スコアを作成する。
前記組織切片上の特定の領域に存在する生体物質を、蛍光物質により蛍光観察可能に染色する領域可視化工程を備える。
組織切片から得られる情報に基づく判断を支援するための、支援情報を提供する情報提供装置であって、
明視野観察可能に染色された組織切片の、デジタル化された明視野画像を取得する画像取得部と、
前記明視野画像から複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成するスコア作成部と、
前記解析スコアを、前記支援情報として提示する情報提示部と、を備える。
組織切片から得られる情報に基づく判断を支援するための、支援情報を提供する情報提供装置のコンピューターを、
明視野観察可能に染色された組織切片の、デジタル化された明視野画像を取得する画像取得部、
前記明視野画像から複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成するスコア作成部、
前記解析スコアを、前記支援情報として提示する情報提示部、
として機能させる。
「領域」とは、同じ構造または細胞が一定量集合して存在する範囲のことを示す。
領域のうち、本実施形態に係る「腫瘍領域」は、後述する腫瘍細胞が一定量集合して形成された領域を示し、「間質領域」は、後述する間質細胞が一定量集合して形成された領域を示す。
2.構造
「構造」とは、細胞が一定量集合して存在し、何らかの生理的活動を行っているものを示す。構造として、例えば、血管、リンパ管、分泌腺等が挙げられる。
3.細胞種
「細胞種」とは、それ一つで機能を持ち、働く最小の単位の細胞の種類を示す。
細胞種のうち、本実施形態における「腫瘍細胞」は、生体内の制御に反して自律的に過剰に増殖する細胞を示し、悪性腫瘍を形成する「がん細胞」を含む。「間質細胞」は、生体組織の支持構造を形成する細胞を広く示し、免疫細胞、炎症細胞、線維芽細胞、内皮細胞等を含む。なお、がん細胞と間質細胞とが密接に相互作用を行うことにより、がんが進行していくことが知られている。
図1に、本実施形態に係る情報提供方法を実行する病理診断支援システム100の全体構成例を示す。病理診断支援システム100は、所定の染色試薬で染色された組織切片の顕微鏡画像を取得及び解析し、支援情報を出力するシステムである。
従来、組織切片に存在する特定の領域、構造、細胞種に係る情報や、組織切片に存在する特定の生体物質の発現量や生体に投与された医薬品の有効成分の局在などの情報に基づき、生体に投与された医薬品の薬効予測、観察対象の予後予測又は病理診断などの種々の判断が行われる。このような判断は、病理医や医薬品開発の従事者等のユーザーのみならず、近年では人工知能を用いて自動的にこれらの情報を認識し、判断することも行われている。本実施形態に係る支援情報は、これらの判断の精度向上を支援するために提供される。具体的には、支援情報は、組織切片上の特定の領域、構造、細胞種の存在数や配置などの情報に基づいて算出される解析スコアの形態をとることができるが、上述した種々の判断をサポートするための、客観的かつ高精度な指標として機能する。
病理診断支援システム100は、顕微鏡画像取得装置1Aと情報提供装置2Aとが、同一の建物内など互いに近傍に配置されるシステムである場合と、顕微鏡画像取得装置1Aと情報提供装置2Aとが、互いに遠く離れた地点に配置されるシステムである場合と、のどちらであってもよい。通信ネットワークNは特に限定されず、接続方式は有線であっても無線であってもよいが、顕微鏡画像取得装置1Aと情報提供装置2Aとが近傍に配置される場合、例えばLAN(Local Area Network)が挙げられ、顕微鏡画像取得装置1Aと情報提供装置2Aとが遠隔地に配置される場合、例えばインターネットなどのWAN(Wide Area Network)が挙げられる。
顕微鏡画像取得装置1Aは、照射手段、結像手段、撮像手段、通信I/F等を備えて構成されている。照射手段は、光源、フィルター等により構成され、スライド固定ステージに載置されたスライド上の組織切片に光を照射する。結像手段は、接眼レンズ、対物レンズ等により構成され、照射した光によりスライド上の組織切片から発せられる透過光、反射光、又は蛍光を結像する。撮像手段は、CCD(Charge Coupled Device)センサー等を備え、結像手段により結像面に結像される像を撮像して顕微鏡画像のデジタル画像データを生成する顕微鏡設置カメラである。通信I/Fは、生成された顕微鏡画像のデジタル画像データを、通信ネットワークNを介して情報提供装置2Aに送信する。本実施の形態において、顕微鏡画像取得装置1Aは、明視野観察に適した照射手段及び結像手段を組み合わせた明視野ユニット、蛍光観察に適した照射手段及び結像手段を組み合わせた蛍光ユニットが備えられており、前者を用いて明視野画像、後者を用いて蛍光画像をそれぞれ取得することができる。
即ち、顕微鏡画像取得装置1Aと情報提供装置2Aとが互いに遠く離れた地点に配置された場合であっても、ユーザーが情報提供装置2Aによって、遠隔地から顕微鏡画像取得装置によって取得された情報を利用することが可能である。
図2に、情報提供装置2Aの機能構成例を示す。図2に示すように、情報提供装置2Aは、制御部21、操作部22、表示部23、通信I/F24、記憶部25等を備えて構成され、各部はバス26を介して接続されている。
その他、情報提供装置2Aは、LANアダプターやルーター等を備え、通信ネットワークNを介して外部機器と接続される構成としてもよい。
以下、本実施形態に係る情報提供方法について説明する。
本発明に係る情報提供方法は、観察対象の薬効予測、予後予測、又は病理診断などの、組織切片から得られる情報に基づく種々の判断を支援するための支援情報の提供方法である。
また、上記工程に加えて、4.蛍光物質集積ナノ粒子を用いて染色された組織切片の、デジタル化された蛍光画像を取得する工程(画像取得工程)と、を有し、スコア作成工程において、明視野画像から取得された情報に加え、蛍光画像から取得された情報を組み合わせてスコア化した解析スコアを作成するものとすることで、支援情報の精度を向上させることができる。
本実施形態に係る情報提供方法においては、上記1~4の工程を有し、明視野画像及び蛍光画像から得られる情報に基づいて解析スコアを作成する。
組織標本とは、一般的には、免疫組織化学染色により特定の生体物質の発現量を評価する場合などで慣用されているような、組織切片や細胞を載置した標本スライドの形態をとる。本実施形態においては、腫瘍組織から採取した組織切片を用いるものとする。
組織標本の作製法は特に限定されず、一般的には、例えば、被験体から採取した組織切片を、ホルマリン等を用いて固定し、アルコールで脱水処理した後、キシレン処理を行い、高温のパラフィン中に浸すことでパラフィン包埋を行うことで作製した組織試料を3~4μmの切片にすることで得ることができ、当該組織切片をスライドガラス上に載置して乾燥することで標本スライドを作製することができる。
以下、組織標本を、染色試薬を用いて染色する染色工程について述べる。
(2.1.1)脱パラフィン処理
キシレンを入れた容器に、組織切片を浸漬させ、パラフィン除去する。温度は特に限定されるものではないが、室温で行うことができる。浸漬時間は、3分以上30分以下であることが好ましい。また必要により浸漬途中でキシレンを交換してもよい。
後述する蛍光染色工程において目的物質の染色を行うため、公知の方法に倣い、当該目的物質の賦活化処理を行う。賦活化条件に特に定めはないが、賦活液としては、0.01Mのクエン酸緩衝液(pH6.0)、1mMのEDTA溶液(pH8.0)、5%尿素、0.1Mのトリス塩酸緩衝液などを用いることができる。
pH条件は用いる組織切片に応じてpH2.0~13.0の範囲から、シグナルが出て、組織の荒れがシグナルを評価できる程度となる条件で行う。通常はpH6.0~8.0で行うが、特殊な組織切片ではたとえばpH3.0でも行う。
加熱機器はオートクレーブ、マイクロウェーブ、圧力鍋、ウォーターバスなどを用いることができる。温度は特に限定されるものではないが、室温で行うことができる。温度は50~130℃、時間は5~30分で行うことができる。
形態染色工程は、明視野において細胞、組織、臓器などの形態を観察することができるように可視化させるための染色を行う工程である。
組織標本の形態観察に関しては、細胞質・間質・各種線維・赤血球・角化細胞が赤~濃赤色に染色される、エオジンを用いた染色が標準的に用いられている。細胞核・石灰部・軟骨組織・細菌・粘液が青藍色~淡青色に染色される、ヘマトキシリンを用いた染色も標準的に用いられている(これら2つの染色を同時に行う方法はヘマトキシリン・エオジン染色(HE染色)として知られている)。
形態染色工程は、常法に従って行うことができる。例えば、HE染色の場合、組織標本をマイヤーヘマトキシリン液に浸漬させて、ヘマトキシリン染色を行った後、流水で組織標本を洗浄し、エオジン液に浸漬させて、エオジン染色を行う。形態染色工程を行う上での条件、すなわち染色液に組織標本を浸漬する際の温度および浸漬時間等は、定法に準じて適宜調整することができる。
蛍光染色工程は、目的物質を蛍光物質集積ナノ粒子によって蛍光観察を行うための染色を行う工程である。蛍光染色工程では、目的物質を染色するために、免疫染色剤の溶液を切片に乗せ、目的物質と反応させる、免疫組織化学染色を行う。蛍光染色工程に用いる免疫染色剤の溶液については、この工程の前にあらかじめ調製しておけばよい。
なお、蛍光染色工程は、形態染色工程の後に行うようにしてもよいし、形態染色工程の前に行うようにしてもよい。
目的物質とは、主に病理診断の観点からの検出または定量のために、蛍光標識体を用いた免疫組織化学染色の対象とするものをいう。具体的には、組織切片に存在するタンパク質(抗原)、核酸などの生体物質が想定される。さらに、生体に投与される医薬品(抗体医薬や核酸医薬など)に含まれる抗体や核酸なども目的物質の例として挙げられる。本実施形態においては、目的物質として、以下に例示する生体物質のうちいずれかを染色するものとする。
タンパク質としては、免疫細胞に発現しており、バイオマーカーとして利用することができるタンパク質を挙げることができる。例えば、PD-1、CTLA-4、TIM3、Foxp3、CD3、CD4、CD8、CD25、CD27、CD28、CD70、CD40、CD40L、CD80、CD86、CD160、CD57、CD226、CD112、CD155、OX40(CD134)、OX40L(CD252)、ICOS(CD278)、ICOSL(CD275)、4-1BB(CD137)、4-1BBL(CD137L)、2B4(CD244)、GITR(CD357)、B7-H3(CD276)、LAG-3(CD223)、BTLA(CD272)、HVEM(CD270)、GITRL、ガレクチン-9(Galectin-9)、B7-H4、B7-H5、PD-L2、KLRG-1、E-Cadherin、N-Cadherin、R-CadherinおよびIDO、TDO、CSF-1R、HDAC、CXCR4、FLT-3、TIGITなどが挙げられるが、これらに限定されない。
核酸としては、DNAやRNA関連物質(mRNA、tRNA、rRNA、miRNA、non-codingRNAなど)などが挙げられる。
抗体を成分に含む医薬品としては、抗体を有効成分として含む医薬品のほか、抗がん剤、抗ウイルス剤、抗生物質等を有効成分とし、がん細胞へのデリバリー手段としてがん細胞特異的タンパク質を認識する抗体が含まれる医薬品や、有効成分が標的とする因子(タンパク質)の関連するシグナル伝達経路の因子を標的とする抗体を含む医薬品等が挙げられる。これらの医薬品に含まれる抗体としては、がんの増殖制御因子、転移制御因子又はがん細胞特異的タンパク質などを特異的に認識する抗体が好ましく、モノクローナル抗体でもポリクローナル抗体でも良い。抗体のクラスやサブクラスは特に限定されず、クラスとしては、IgA、IgG、IgE、IgD、IgMなどを挙げることができ、サブクラスとしては、IgG1、IgG2、IgG3、IgG4、IgA1、IgA2などを挙げることができる。なお、本明細書における「抗体」という用語には、全長の抗体だけでなく、Fab、F(ab)’2、Fv、scFvなどの抗体断片およびキメラ抗体(ヒト化抗体等)、多機能抗体などの誘導体が包含される。
核酸を成分に含む医薬品としては、DNA若しくはRNAである核酸、又はPNA等の人工核酸であれば特に限定されず、好ましい例としてデコイ、アンチセンス、siRNA、miRNA、リボザイム、アプタマー及びプラスミドDNA等を挙げることができる。
蛍光物質集積ナノ粒子(Phosphor Integrated Dot:PID)とは、励起光の照射を受けて蛍光発光するナノサイズの粒子であって、目的物質を1分子ずつ輝点として表すのに十分な強度の蛍光を発光しうる粒子である。
蛍光物質集積ナノ粒子は、有機物または無機物でできた粒子を母体とし、複数の蛍光物質(例えば、後述する蛍光有機色素や量子ドットなど)がその中に内包されている及び/又はその表面に吸着している構造を有する、ナノサイズの粒子であり、蛍光色素集積ナノ粒子、量子ドット集積ナノ粒子などが使用される。
蛍光物質集積ナノ粒子としては、母体と蛍光物質とが、互いに反対の電荷を有する置換基または部位を有し、静電的相互作用が働くものであることが好適である。
蛍光画像の取得のための染色試薬に用いられる蛍光物質としては、蛍光有機色素及び量子ドット(半導体粒子)を挙げることができる。200~700nmの範囲内の波長の紫外~近赤外光により励起されたときに、400~1000nmの範囲内の波長の可視~近赤外光の発光を示すことが好ましい。
量子ドットは必要に応じて、有機ポリマー等により表面処理が施されているものを用いてもよい。例えば、表面カルボキシ基を有するCdSe/ZnS(インビトロジェン社製)、表面アミノ基を有するCdSe/ZnS(インビトロジェン社製)等が挙げられる。
母体のうち、有機物としては、メラミン樹脂、尿素樹脂、アニリン樹脂、グアナミン樹脂、フェノール樹脂、キシレン樹脂、フラン樹脂など、一般的に熱硬化性樹脂に分類される樹脂;スチレン樹脂、アクリル樹脂、アクリロニトリル樹脂、AS樹脂(アクリロニトリル-スチレン共重合体)、ASA樹脂(アクリロニトリル-スチレン-アクリル酸メチル共重合体)など、一般的に熱可塑性樹脂に分類される樹脂;ポリ乳酸等のその他の樹脂;多糖を例示することができる。
母体のうち、無機物としては、シリカ、ガラスなどを例示することができる。
量子ドット集積ナノ粒子とは、上記量子ドットが、上記母体の中に内包されている、及び/又はその表面に吸着している構造を有する。
量子ドットが母体に内包されている場合、量子ドットは母体内部に分散されていればよく、母体自体と化学的に結合していてもよいし、していなくてもよい。
蛍光色素集積ナノ粒子とは、上記蛍光有機色素が、上記母体の中に内包されている、及び/又はその表面に吸着している構造を有する。
なお、蛍光有機色素が母体に内包されている場合、蛍光有機色素は母体内部に分散されていればよく、母体自体と化学的に結合していてもよいし、していなくてもよい。
蛍光物質集積ナノ粒子は、公知の方法に従って作製することができる。
具体的には、例えば、シリカを母体とし、その中に蛍光物質が内包されている蛍光物質内包シリカ粒子は、量子ドット、蛍光有機色素などの蛍光物質と、テトラエトキシシランのようなシリカ前駆体とが溶解している溶液を、エタノールおよびアンモニアが溶解している溶液に滴下し、シリカ前駆体を加水分解することにより作製することができる。
例えば、母体となる樹脂としてメラミン樹脂のような熱硬化性樹脂を用いる場合、その樹脂の原料(モノマーまたはオリゴマーないしプレポリマー、たとえばメラミンとホルムアルデヒドの縮合物であるメチロールメラミン)と、蛍光有機色素と、好ましくはさらに界面活性剤および重合反応促進剤(酸など)とを含有する反応混合物を加熱し、乳化重合法によって重合反応を進行させることにより、蛍光色素集積樹脂粒子を作製することができる。また、母体となる樹脂としてスチレン系共重合体のような熱可塑性樹脂を用いる場合、その樹脂の原料と、蛍光有機色素と(樹脂の原料モノマーとして、あらかじめ有機蛍光色素を共有結合などで結合させたモノマーを用いるようにしてもよい)、重合開始剤(過酸化ベンゾイル、アゾビスイソブチロニトリルなど)を含有する反応混合物を加熱し、ラジカル重合法またはイオン重合法によって重合反応を進行させることにより、蛍光色素集積樹脂粒子を作製することができる。
本実施の形態で用いられる蛍光物質集積ナノ粒子の平均粒径は特に限定されないが、粒子径が大きいものは抗原にアクセスしにくく、粒子径が小さく輝度値が低いものは蛍光物質集積ナノ粒子の信号がバックグラウンドノイズ(カメラのノイズや細胞の自家蛍光)に埋もれてしまうことから、20~500nm程度のものが好適である。
また、粒径のばらつきを示す変動係数(=(標準偏差/平均値)×100%)は特に限定されないが、20%以下のものを用いることができ、好ましくは5~15%である。
平均粒径は、走査型電子顕微鏡(SEM)を用いて電子顕微鏡写真を撮影し十分な数の粒子について断面積を計測し、各計測値を円の面積としたときの円の直径を粒径として求めた。本願においては、1000個の粒子の粒径の算術平均を平均粒径とした。変動係数も、1000個の粒子の粒径分布から算出した値とした。
一次抗体には、目的物質としてのタンパク質を抗原として特異的に認識して結合する抗体(IgG)を用いることができる。
なお、一次抗体は、特定の生体物質(抗原)を特異的に認識して結合する能力を有するものであれば、天然の全長の抗体でなく、抗体断片または誘導体であってもよい。
免疫染色剤は、目的物質に直接的又は間接的に結合しうる抗体と標識物質とを、直接的又は間接的に結合させた標識化抗体を、適当な媒体に分散させて生成される。
なお、蛍光標識の効率を向上させて蛍光の劣化につながる時間経過をなるべく抑えるためには、一次抗体および蛍光物質集積ナノ粒子が間接的に、つまり抗原抗体反応やアビジン・ビオチン反応などを利用した、共有結合以外の結合によって連結される複合体を用いることが好ましいが、これに限定されない。
蛍光物質集積ナノ粒子が樹脂を母体とする場合、その樹脂が有する官能基と、アビジン(タンパク質)が有する官能基とを、必要に応じて分子の両末端に官能基を有するPEG等のリンカー分子を介することにより、結合させることができる。例えば、メラミン樹脂であればアミノ基等の官能基を利用することができるし、アクリル樹脂、スチレン樹脂等であれば、側鎖に官能基(たとえばエポキシ基)を有するモノマーを共重合させることにより、その官能基自体またはその官能基から変換された官能基(例えばアンモニア水を反応させることにより生成するアミノ基)を利用することができるし、さらにはそれらの官能基を利用して別の官能基を導入することもできる。
一方、アビジンに対しては、たとえばN-スクシンイミジルS-アセチルチオアセテート(SATA)をアビジンのアミノ基と反応させることにより、チオール基を導入することができる。そして、アミノ基との反応性を有するN-ヒドロキシスクシンイミド(NHS)エステルおよびチオール基との反応性を有するマレイミド基をポリエチレングリコール(PEG)鎖の両端に有するクロスリンカー試薬を利用することにより、アミノ基を有する蛍光物質集積ナノ粒子と、チオール基が導入されたアビジンとを連結することができる。
温度は特に限定されるものではないが、室温で行うことができる。反応時間は、30分以上24時間以下であることが好ましい。
上述したような処理を行う前に、BSA含有PBSなど公知のブロッキング剤やTween20などの界面活性剤を滴下することが好ましい。
形態染色工程及び蛍光染色工程を終えた組織標本は、観察に適したものとなるよう、固定化・脱水、透徹、封入などの処理を行うことが好ましい。
これらの処理を行う上での条件、たとえば組織標本を所定の処理液に浸漬する際の温度および浸漬時間は、従来の免疫染色法に準じて、適切なシグナルが得られるよう適宜調整することができる。
画像取得工程では、まず、顕微鏡画像取得装置1Aを明視野ユニットに設定したうえで所望の倍率に設定し、形態染色工程によって染色された組織標本全体の明視野画像を観察・撮影する。
次いで、顕微鏡画像取得装置1Aを蛍光ユニットに設定し、蛍光染色工程に用いられた目的物質を蛍光標識するそれぞれの蛍光物質に対応した励起光を組織標本に照射し、それらの蛍光物質から発せられた蛍光による組織標本全体の蛍光画像を観察・撮影する。
スコア作成工程では、まず明視野画像における領域、構造及び細胞種などの複数種の情報を取得し、各々の情報を組み合わせてスコア化した形態スコアを算出する。
画像処理及びスコア化に用いることができるソフトウェアとしては、例えば「ImageJ」(オープンソース)が挙げられる。このような画像処理ソフトウェアを利用することにより、一細胞ごとに識別可能に染色された明視野画像から、細胞ごとの形状や、細胞が集まって形成された領域、構造の形状に基づいて、領域、構造及び細胞種の判別を行う処理や、領域、構造及び細胞種の数、面積などの情報に基づいてスコアを算出する処理などを半自動的に、迅速に行うことができる。
画像処理及び発現解析にも、上記した「ImageJ」(オープンソース)などのソフトウェアを利用することができる。即ち、蛍光画像から、所定の波長(色)の輝点を抽出し、そのうち所定の輝度以上の輝点の数を計測する処理などを半自動的に、迅速に行うことができる。
本実施形態に係る病理診断支援システム100においては、必要に応じて、腫瘍領域と間質領域とを識別するための蛍光染色を行う工程を含むことができる。即ち、例えば間質領域に多く存在する物質を蛍光標識し、蛍光観察を行うことで、蛍光が観測される間質領域と、蛍光が観察されないか、あるいは微弱な傾向が観察される腫瘍領域との境界を、ユーザーが蛍光観察によって確認することが可能となる。これにより、明視野画像に基づく腫瘍領域と間質領域との識別をサポートすることができる。
具体的には、以下の染色が有効である。
間質領域中に存在するサイトカインを蛍光標識することで、腫瘍領域と間質領域を蛍光観察によって明確に識別することができる。即ち、腫瘍領域に比べ、間質領域においてはサイトカインが多量に存在するため、蛍光輝度の違いにより腫瘍領域と間質領域との境界を視認することができる。
本工程においては、サイトカインを抗原として特異的に認識して結合する抗体(IgG)を用い、当該抗体を蛍光物質で標識した免疫染色剤を用いて組織標本を染色する。なお、蛍光標識に用いる蛍光物質は、蛍光物質集積ナノ粒子に限定されず、単体の蛍光色素を用いても腫瘍領域と間質領域とを十分に識別することができる。
具体的には、上記「(2.3)蛍光染色工程」と同様の手順によって染色することができる。また、サイトカインの蛍光染色は、上記「(2.3)蛍光染色工程」における目的物質の蛍光染色と同時に行うことが可能である。ただし、目的物質を標識した蛍光物質集積ナノ粒子とは、蛍光波長の異なる蛍光物質を用いることが望ましい。
サイトカインの例としては、IL-1、IL-2、IL-4、IL-6、IL-10、IL-12、IL-18、IFN-α、IFN-β、IFN-γ、TNF、TGF-βが挙げられる。
免疫細胞におけるタンパク質とは、ここでは免疫細胞に特異的に発現するタンパク質を指し、これを蛍光標識することでも、腫瘍領域と間質領域を蛍光観察によって明確に識別することができる。即ち、間質領域における免疫細胞に基づく蛍光輝度が、腫瘍領域における免疫細胞に基づく蛍光輝度に比べて大幅に大きいため、輝度の違いから領域の境界を視認することができる。なお、上記「(2.3)蛍光染色工程」において間質領域に高発現するタンパク質の蛍光染色を行う場合には、目的物質の蛍光観察によって本工程を代替することができるが、これを行わない場合には、本工程で以下に例示するタンパク質を蛍光染色することが有効である。
本工程においては、免疫細胞におけるタンパク質を抗原として特異的に認識して結合する抗体(IgG)を用い、当該抗体を蛍光物質で標識した免疫染色剤を用いて組織標本を染色する。蛍光標識をするための蛍光物質は、蛍光物質集積ナノ粒子に限定されず、単体の蛍光色素でも腫瘍領域と間質領域とを十分に識別することができる。なお、染色は、上記「(2.3)蛍光染色工程」同様の手順によって行うことができる。
免疫細胞におけるタンパク質の例としては、PD-1、CTLA-4、TIM3、Foxp3、CD3、CD4、CD8、CD25、CD27、CD28、CD70、CD40、CD40L、CD80、CD86、CD160、CD57、CD226、CD112、CD155、OX40(CD134)、OX40L(CD252)、ICOS(CD278)、ICOSL(CD275)、4-1BB(CD137)、4-1BBL(CD137L)、2B4(CD244)、GITR(CD357)、B7-H3(CD276)、LAG-3(CD223)、BTLA(CD272)、HVEM(CD270)、GITRL、ガレクチン-9(Galectin-9)、B7-H4、B7-H5、PD-L2、KLRG-1、E-Cadherin、N-Cadherin、R-CadherinおよびIDO、TDO、CSF-1R、HDAC、CXCR4、FLT-3、TIGITが挙げられる。
以下、病理診断支援システム100において、上記説明した蛍光画像及び明視野画像を取得して解析を行う動作について説明する。ここでは、免疫細胞において発現するタンパク質から任意のものを目的物質として選択し、当該目的物質を認識する生体物質認識部位が結合した蛍光物質集積ナノ粒子を含む染色試薬を用いて染色された組織標本を観察対象とする場合を例にとり説明する。
その後、顕微鏡画像取得装置1Aにおいて、(a1)~(a5)の手順により明視野画像及び蛍光画像が取得される。
(a1)操作者は、HE染色試薬と蛍光物質集積ナノ粒子を含む染色試薬とによりそれぞれ染色された組織標本をスライドに載置し、当該スライドを顕微鏡画像取得装置1Aのスライド固定ステージに設置する。
(a2)明視野ユニットに設定し、撮影倍率、ピントの調整を行う。
(a3)撮像手段で組織標本全体の撮影を行って明視野画像の画像データを生成し、情報提供装置2Aに画像データを送信する。
(a4)ユニットを蛍光ユニットに変更する。
(a5)視野及び撮影倍率を変えずに撮像手段で組織標本全体の撮影を行って蛍光画像の画像データを生成し、情報提供装置2Aに画像データを送信する。
図3に、情報提供装置2Aにおける処理のフローチャートを示す。図3に示す処理は、制御部21と記憶部25に記憶されているプログラムとの協働により実行される。
図4に、ステップS2における処理の詳細フローを示す。ステップS2の処理は、制御部21と記憶部25に記憶されているプログラムとの協働により実行される。
図5に、ステップS21における処理の詳細フローを示す。ステップS21の処理は、制御部21と記憶部25に記憶されているプログラムとの協働により実行される。
具体的には、まず、明視野画像がモノクロ画像に変換され、モノクロ画像に対してあらかじめ定められた閾値を用いた閾値処理が施され、各画素の値が2値化される。
さらに、クロージング処理やオープニング処理が施されることによりノイズ処理が実施される。ノイズ処理後には、細胞核が抽出された画像(細胞核画像)が得られる。
次いで、ノイズ処理後の画像にラベリング処理が施され、抽出された細胞核のそれぞれにラベルが付与される。ラベリング処理とは、連結している画素に同じラベル(番号)を付与していくことで画像内のオブジェクトを識別する処理である。ラベリング処理により、ノイズ処理後の画像から各細胞核を識別してラベルを付与することができる。
なお、ステップS211においては、細胞核を抽出する方法の他、細胞自体を抽出するものとしてもよい。この場合、ノイズ処理後には細胞が抽出された画像が取得され、ラベリング処理により各細胞にラベルが付与される。
具体的には、ステップS211で抽出された細胞核画像内の全細胞核について、細胞核画像から、細胞核の面積A、細胞核の平均濃度B、細胞核内のピクセル輝度バラつき(σ値)C、細胞核の円形度D、細胞核の扁平率Eなどの細胞特徴量が算出される。
細胞核の面積Aについては、予め細胞核画像に対応した基準となる長さを測定することで画素(ピクセル)の大きさを算出し、ステップ211で抽出された各細胞核内の画素数を積算することにより、細胞核の面積Aが決定される。
細胞の平均濃度Bは、細胞核内の各画素(ピクセル)のグレイスケールに変換した輝度信号値を求め、その平均値を算出することにより決定される。
ピクセル輝度バラツキCは、細胞核内の各画素(ピクセル)の輝度信号値の標準偏差を算出することにより決定される。
細胞核の円形度D及び扁平率Eは、ステップ211で抽出された各細胞核について、細胞核画像から得られる一定の値を、下記式(d)、(e)に当てはめることで決定される。
(円形度D)=4πS/L2 … (d)
(扁平率E)=(a-b)/a … (e)
ただし、式(d)中、「S」は細胞の面積(細胞核の面積A)を、「L」は細胞核の外周長をそれぞれ表す。式(e)中、「a」は長半径を、「b」は短半径をそれぞれ表す。
ステップS22においては、例えば、細胞核画像から細胞が一定量集合して形成された構造を抽出する。続いて、抽出された各構造から、構造の面積、平均輝度、輝度のばらつき、扁平率、円形度などの特徴量を算出し、当該特徴量に基づいて、血管、リンパ管、分泌腺などを識別する。
領域の特定においては、腫瘍細胞が一定量集合して存在する腫瘍領域と、間質細胞が一定量集合して存在する間質領域と、が特定される。
ステップS23においては、例えば、ステップS21において細胞核画像上で腫瘍細胞と特定された細胞(細胞核)の集合が、所定の面積以上を占めている場合に、当該腫瘍細胞の集合を腫瘍領域として特定することができる。同様に、ステップS21において間質細胞と特定された細胞(細胞核)の集合が、所定の面積以上を占めている場合に、当該間質細胞の集合を間質領域として特定することができる。
ステップS23の処理により、スコア算出対象の特定が完了する。
ユーザーによる補助作業とは、例えば、ステップS21の領域の特定処理においては、入力された情報提供装置2Aの表示部23に表示された明視野画像に対して、ユーザーによって明視野画像上の特定の領域を、操作部22を用いて多角形や自由曲線等の閉じた図形で囲むことにより選択し、各選択箇所を「腫瘍領域」、「間質領域」など定義づける動作を含む。また、蛍光画像における蛍光を観察することにより、明視野画像における領域の特定処理の結果を確認する動作を含む。
ステップS22の構造の特定処理及びステップS23の細胞種の特定処理においても、同様にユーザーによって明視野画像上で選択及び定義づけする動作を含む。
また、ステップS233の細胞特徴量の閾値処理においては、例えば、記憶部25に記憶されているプログラムに対し細胞特徴量の各閾値を段階的に調整し、特定された細胞種の目視による確認等を含む。
図6に、ステップS3における処理の詳細フローを示す。ステップS24の処理は、制御部21と記憶部25に記憶されているプログラムとの協働により実行される。
領域に基づくスコアとは、組織切片上に存在する腫瘍領域及び間質領域などの種々の領域から得られる情報をスコア化したものである。腫瘍領域の大きさはがんの悪性度と関連付けられるため、例えば、撮像した組織切片の全体の面積のうちの腫瘍領域が占める割合や、全体の面積のうちの腫瘍領域及び間質領域が占める面積の割合、間質領域の面積と腫瘍領域の面積の比などをスコア化することが有効である。
構造に基づくスコアとは、組織切片上に存在する血管、リンパ管及び分泌管など種々の構造から得られる情報をスコア化したものである。血管の密度ががんの悪性度の評価指標となることが知られているため、例えば、がんの悪性度に関連する構造の、組織切片上の存在の有無、密度又は出現数などをスコア化することが有効である。
細胞種に基づくスコアとは、組織切片上に存在する腫瘍細胞、間質細胞などの細胞種から得られる情報をスコア化したものである。例えば、がん細胞及び正常細胞のそれぞれの、組織切片上に存在する数をスコア化してもよい。また、これらのがん細胞の組織切片上の密度や、腫瘍領域におけるがん細胞と、間質領域における免疫細胞との距離など、異なる細胞種間の距離や、腫瘍領域におけるがん細胞と間質領域における血管との距離などの、特定の細胞出と特定の構造との距離といった、病理診断において注目される種々の情報をスコア化してもよい。
ステップS33の処理により、形態スコアの算出が完了し、図3に戻る。
また、上記した領域スコア、構造スコア及び細胞種スコアの算出方法は一例であって、これに限定されない。その他、病理診断において注目される項目をスコア化するのが望ましい。
ステップS5においては、まず、蛍光画像からR成分の抽出が行われ、R成分が抽出された画像にTophat変換が施される。Tophat変換は、入力画像の各画素の値から、入力画像に最小値フィルター及び最大値フィルターをこの順でかけた画像の、対応する画素の値を減算する処理である。最小値フィルターは、注目画素の近傍の画素(例えば、3×3画素)のうちの最小値で注目画素の値を置き換えるものである。最大値フィルターは、注目画素の近傍の画素(例えば、3×3画素)のうちの最大値で注目画素の値を置き換えるものである。Tophat変換により、濃淡プロファイル上の小突起(近傍の画素に比べて輝度の高い領域)を抽出することができる。これにより、蛍光輝点候補画像を得ることができる。次いで、蛍光輝点候補画像からノイズ除去が行われることにより、蛍光輝点が抽出された画像(蛍光輝点画像)が得られ、ノイズ除去後の画像にラベリング処理が施され、抽出された蛍光輝点のそれぞれにラベルが付与される。
図7に、ステップS6における処理の詳細フローを示す。ステップS6の処理は、制御部21と記憶部25に記憶されているプログラムとの協働により実行される。
明視野画像と蛍光画像とで共通に検出される情報源としては、明視野画像及び蛍光画像の両方で認識可能な情報が用いられ、本実施形態では組織切片の染色材料であるエオジンの染色情報が用いられる。エオジンの染色情報からは、明視野画像及び蛍光画像の各画像においてその画像を特徴付けるコントラスト情報やエッジ情報、輪郭情報等の画像特徴量が算出される。
明視野画像及び蛍光画像のそれぞれのエオジンの染色情報から、各画像におけるコントラスト情報、エッジ情報及び輪郭情報が算出される。そしてこれら画像間の情報同士が比較され、その共通点を合致させることにより、明視野画像と蛍光画像との位置合わせが行われる。
具体的には、例えば、明視野画像と蛍光画像とを重ね合わせた状態において、ステップS23で特定した細胞に対応する部分の蛍光輝点数が算出される。また、蛍光輝点数のほか、輝点領域ごとに輝度値を算出し、その蛍光画像中のすべての輝点領域の輝度値を総計した輝度積分値を算出するものとしてもよい。
存在状況に応じたスコアは、一細胞当たりの目的物質の存在量や細胞内局在等に応じて算出されるスコアである。なお、複数の目的物質を蛍光染色した場合には、ステップS5及びステップS6の処理は各目的物質について行い、各目的物質についての生体物質スコアを得ることができる。
ステップS63により、生体物質スコアの算出を完了する。
解析スコアの算出は、ステップS3で算出した形態スコアと、ステップS6で算出した生体物質スコアを合算することで行われる。
なお、形態スコア及び生体物質スコアの合算に際して、ユーザーが欲する支援情報を得られるように、任意の重みづけを行ってもよい。
以上により、情報提供装置2Aにおける処理を終了する。
また、組織切片の画像をデジタル解析して評価を行うため、病理医等による主観的な判断に比べ、客観的な情報を提供することができ、本実施形態に係る情報提供方法によって病理診断等の種々の判断がサポートされ、精度の向上を図ることができる。
さらに、腫瘍領域におけるがん細胞と間質領域における免疫細胞との距離や、がん細胞と血管などの特定の構造との距離など、領域、構造及び細胞種の間の局在の関係性に係る情報を用いて解析スコアを作成することで、より信頼性の高い支援情報を提供することができる。
また、領域、構造及び細胞種のそれぞれについてスコア化することを基本とし、目的に応じてスコア化する項目及び重みづけを設定することで、ユーザーが欲する情報をスコアとして提示することができる。
本発明は、上記したように、病理切片から得られる情報を自動的にスコア化して提示することで病理医等による種々の判断をサポートすることを目的とするが、これは、明視野画像から得られる複数種の情報(領域、構造及び細胞種に係る情報)を組み合わせたスコアによって、実際に病理医等が判断を行う際の判断基準に近い方法で病理切片を評価した結果を得ることができるため、十分にその目的を達成することができる。
即ち、特許文献1及び特許文献2のように、生体物質を蛍光染色することが必ずしも必要ではなく、形態染色工程のみによっても解析スコアを作成することが可能であるため、染色ごとのスライド間のばらつきや手間を省略することができる。
図8Aは、被検体から採取された組織切片にHE染色を施した組織標本を、顕微鏡画像取得装置1Aの明視野ユニットを用いて撮影して得られた明視野画像200である。図8Aに示すように、明視野画像200上に、腫瘍領域210及び間質領域220が存在し、間質領域220には血管230が存在する。
なお、組織切片は、蛍光物質集積ナノ粒子を用いて目的物質(HER2)を染色しており、図示を省略するが、顕微鏡画像取得装置1Aの蛍光ユニットを用いて、明視野画像200と同一の視野の蛍光画像を取得した。
まず、領域面積をスコア化する(ステップS101)。ここでは、腫瘍領域210及び間質領域220の面積が、組織標本全体の面積に占める割合をスコア化した値N1を算出するものとし、N1を、(腫瘍領域210及び間質領域220の面積/明視野画像200の面積)の式で得られる値を規格化した値とする。
図8Aの組織標本からは、N1=40が得られた。
図8Aの組織標本においては、間質領域220に血管230が観察されるため、N2=20が得られた。
図8Aの組織標本においては、血管230が所定の数よりも多いため、N3=(N1+N2)×2=(40+20)×2=120が得られた。
図8Aの組織標本からは、N4=30が得られた。
図8Aの組織標本においては、腫瘍細胞の密度が所定の密度よりも高いため、N5=10が得られた。
ここでは、組織標本上の腫瘍領域210における腫瘍細胞と、間質領域220における免疫細胞との距離が、所定の距離よりも短い(細胞同士が近い)場合には、N6=(N4+N5)×2とし、所定の距離よりも大きい(細胞同士が遠い)場合には、N6=(N4+N5)×1とする。
図8Aの組織標本においては、細胞間距離が所定の距離よりも小さいためN6=(N4+N5)×2=(30+10)×2=80が得られた。
図8Aの組織標本からは、N7=50が得られた。
図8Aの組織標本からは、N=N3+N6+N7=120+80+50=250が得られた。
この解析スコアN=250をユーザーに提示する。例えば、予め解析スコアの数値が、がん悪性度に紐づけられている場合には、ユーザーは解析スコアを参照して被検者のがんの悪性度を判断することができる。このように、解析スコアを病理診断等における種々の指標とすることができる。
以上、本発明を適用した好ましい実施形態について説明したが、上記実施形態における記述内容は、本発明の好適な一例であり、これに限定されるものではない。
1A 顕微鏡画像取得装置
2A 情報提供装置
21 制御部(画像取得部、スコア算出部、情報提示部)
22 操作部
23 表示部
24 通信I/F
25 記憶部
N 通信ネットワーク
Claims (8)
- 組織切片から得られる情報に基づく判断を支援するための、支援情報を提供する情報提供方法であって、
明視野観察可能に染色された組織切片の、デジタル化された明視野画像を取得する画像取得工程と、
前記明視野画像から複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成するスコア作成工程と、
前記解析スコアを、前記支援情報として提示する情報提示工程と、を備える
情報提供方法。 - 前記画像取得工程において、前記組織切片の全体を撮像可能なバーチャル顕微鏡スライド作成装置で撮像することによって得られた、前記組織切片の全体の明視野画像を取得する
請求項1に記載の情報提供方法。 - 前記スコア作成工程において、前記組織切片に存在する領域、構造及び細胞種のうち少なくともいずれか二つに係る複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成する
請求項1又は2に記載の情報提供方法。 - 前記スコア作成工程において、前記組織切片に存在する領域、構造及び細胞種の間の局在の関係性に係る情報を取得する
請求項3に記載の情報提供方法。 - 前記組織切片は、蛍光物質を複数集積した蛍光物質集積ナノ粒子に生体物質認識部位を結合した染色試薬を用いて、当該組織切片に存在する特定の生体物質が蛍光観察可能に染色され、
前記画像取得工程において、さらに、前記組織切片のデジタル化された蛍光画像を取得し、
前記スコア作成工程において、さらに、前記蛍光画像から前記特定の生体物質の存在に係る情報を取得し、前記複数種の情報と組み合わせてスコア化した解析スコアを作成する
請求項3又は4に記載の情報提供方法。 - 前記組織切片上の特定の領域に存在する生体物質を、蛍光物質により蛍光観察可能に染色する領域可視化工程を備える
請求項1から5のいずれか一項に記載の情報提供方法。 - 組織切片から得られる情報に基づく判断を支援するための、支援情報を提供する情報提供装置であって、
明視野観察可能に染色された組織切片の、デジタル化された明視野画像を取得する画像取得部と、
前記明視野画像から複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成するスコア作成部と、
前記解析スコアを、前記支援情報として提示する情報提示部と、を備える
情報提供装置。 - 組織切片から得られる情報に基づく判断を支援するための、支援情報を提供する情報提供装置のコンピューターを、
明視野観察可能に染色された組織切片の、デジタル化された明視野画像を取得する画像取得部、
前記明視野画像から複数種の情報を取得し、当該複数種の情報を組み合わせてスコア化した解析スコアを作成するスコア作成部、
前記解析スコアを、前記支援情報として提示する情報提示部、
として機能させるためのプログラム。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/429,246 US20220138937A1 (en) | 2019-02-15 | 2020-02-06 | Information provision method, information provision device, and storage medium |
JP2020572199A JPWO2020166469A1 (ja) | 2019-02-15 | 2020-02-06 | 情報提供方法、情報提供装置及びプログラム |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-025027 | 2019-02-15 | ||
JP2019025027 | 2019-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020166469A1 true WO2020166469A1 (ja) | 2020-08-20 |
Family
ID=72045593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/004478 WO2020166469A1 (ja) | 2019-02-15 | 2020-02-06 | 情報提供方法、情報提供装置及びプログラム |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220138937A1 (ja) |
JP (1) | JPWO2020166469A1 (ja) |
WO (1) | WO2020166469A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024014489A1 (ja) * | 2022-07-12 | 2024-01-18 | 国立大学法人東京工業大学 | 解析システム、解析装置、解析プログラム、及び解析方法 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS594745B2 (ja) * | 1976-10-09 | 1984-01-31 | 株式会社東芝 | 細胞診装置 |
JPH10197522A (ja) * | 1997-01-14 | 1998-07-31 | Mitsubishi Electric Corp | 病理組織診断支援装置 |
JP2002514319A (ja) | 1997-03-03 | 2002-05-14 | バクス リサーチ ラボラトリーズ インコーポレイテッド | バーチャル顕微鏡スライドを作成する方法および装置 |
JP2006517663A (ja) * | 2003-02-11 | 2006-07-27 | キネティック リミテッド | 画像解析 |
JP2013537969A (ja) | 2010-09-10 | 2013-10-07 | ユニベルシテ、ド、ベルサイユ‐エステ、カンタン、アン、イブリーヌ | 画像解析による固形腫瘍進行の予後検査 |
WO2015190225A1 (ja) * | 2014-06-12 | 2015-12-17 | コニカミノルタ株式会社 | 診断支援情報生成方法、画像処理装置、診断支援情報生成システム及び画像処理プログラム |
JP2016503167A (ja) * | 2012-12-28 | 2016-02-01 | ザ ユニバーシティー オブ メルボルン | 乳癌予知のための画像分析 |
WO2016093090A1 (ja) * | 2014-12-09 | 2016-06-16 | コニカミノルタ株式会社 | 画像処理装置及び画像処理プログラム |
JP2016518813A (ja) * | 2013-03-15 | 2016-06-30 | ベンタナ メディカル システムズ, インコーポレイテッド | デジタル・ホール・スライドの自動採点のための組織物体に基づく機械学習システム |
US9412006B1 (en) * | 2013-02-25 | 2016-08-09 | Flagship Biosciences, Inc. | Continuous tissue analysis scoring scheme based on cell classifications |
JP2016530505A (ja) | 2013-07-15 | 2016-09-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 固形癌を患う患者の生存期間の予後判定のための方法 |
JP2017511488A (ja) * | 2014-02-24 | 2017-04-20 | ヴェンタナ メディカル システムズ, インク. | CD3、CD8、CD20及びFoxP3の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム |
WO2017126420A1 (ja) * | 2016-01-19 | 2017-07-27 | コニカミノルタ株式会社 | 画像処理装置及びプログラム |
WO2017221592A1 (ja) * | 2016-06-23 | 2017-12-28 | コニカミノルタ株式会社 | 画像処理装置、画像処理方法及び画像処理プログラム |
WO2018067234A1 (en) * | 2016-10-07 | 2018-04-12 | Sony Corporation | Automated nuclei area/number estimation for ihc image analysis |
JP2018525707A (ja) * | 2015-06-11 | 2018-09-06 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションUniversity Of Pittsburgh Of The Commonwealth System Of Higher Education | ヘマトキシリン・エオシン(h&e)染色組織画像における関心領域を調べて、多重化/高多重化蛍光組織画像で腫瘍内細胞空間的不均一性を定量化するシステム及び方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3779433A3 (en) * | 2010-08-30 | 2021-05-19 | Konica Minolta, Inc. | Tissue staining method, tissue evaluation method and biosubstance detection method |
US20140233826A1 (en) * | 2011-09-27 | 2014-08-21 | Board Of Regents Of The University Of Texas System | Systems and methods for automated screening and prognosis of cancer from whole-slide biopsy images |
WO2016006096A1 (ja) * | 2014-07-11 | 2016-01-14 | コニカミノルタ株式会社 | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム |
US11508168B2 (en) * | 2018-10-15 | 2022-11-22 | Upmc | Systems and methods for specimen interpretation |
-
2020
- 2020-02-06 JP JP2020572199A patent/JPWO2020166469A1/ja active Pending
- 2020-02-06 US US17/429,246 patent/US20220138937A1/en active Pending
- 2020-02-06 WO PCT/JP2020/004478 patent/WO2020166469A1/ja active Application Filing
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS594745B2 (ja) * | 1976-10-09 | 1984-01-31 | 株式会社東芝 | 細胞診装置 |
JPH10197522A (ja) * | 1997-01-14 | 1998-07-31 | Mitsubishi Electric Corp | 病理組織診断支援装置 |
JP2002514319A (ja) | 1997-03-03 | 2002-05-14 | バクス リサーチ ラボラトリーズ インコーポレイテッド | バーチャル顕微鏡スライドを作成する方法および装置 |
JP2006517663A (ja) * | 2003-02-11 | 2006-07-27 | キネティック リミテッド | 画像解析 |
JP2013537969A (ja) | 2010-09-10 | 2013-10-07 | ユニベルシテ、ド、ベルサイユ‐エステ、カンタン、アン、イブリーヌ | 画像解析による固形腫瘍進行の予後検査 |
JP2016503167A (ja) * | 2012-12-28 | 2016-02-01 | ザ ユニバーシティー オブ メルボルン | 乳癌予知のための画像分析 |
US9412006B1 (en) * | 2013-02-25 | 2016-08-09 | Flagship Biosciences, Inc. | Continuous tissue analysis scoring scheme based on cell classifications |
JP2016518813A (ja) * | 2013-03-15 | 2016-06-30 | ベンタナ メディカル システムズ, インコーポレイテッド | デジタル・ホール・スライドの自動採点のための組織物体に基づく機械学習システム |
JP2016530505A (ja) | 2013-07-15 | 2016-09-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 固形癌を患う患者の生存期間の予後判定のための方法 |
JP2017511488A (ja) * | 2014-02-24 | 2017-04-20 | ヴェンタナ メディカル システムズ, インク. | CD3、CD8、CD20及びFoxP3の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム |
WO2015190225A1 (ja) * | 2014-06-12 | 2015-12-17 | コニカミノルタ株式会社 | 診断支援情報生成方法、画像処理装置、診断支援情報生成システム及び画像処理プログラム |
WO2016093090A1 (ja) * | 2014-12-09 | 2016-06-16 | コニカミノルタ株式会社 | 画像処理装置及び画像処理プログラム |
JP2018525707A (ja) * | 2015-06-11 | 2018-09-06 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションUniversity Of Pittsburgh Of The Commonwealth System Of Higher Education | ヘマトキシリン・エオシン(h&e)染色組織画像における関心領域を調べて、多重化/高多重化蛍光組織画像で腫瘍内細胞空間的不均一性を定量化するシステム及び方法 |
WO2017126420A1 (ja) * | 2016-01-19 | 2017-07-27 | コニカミノルタ株式会社 | 画像処理装置及びプログラム |
WO2017221592A1 (ja) * | 2016-06-23 | 2017-12-28 | コニカミノルタ株式会社 | 画像処理装置、画像処理方法及び画像処理プログラム |
WO2018067234A1 (en) * | 2016-10-07 | 2018-04-12 | Sony Corporation | Automated nuclei area/number estimation for ihc image analysis |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024014489A1 (ja) * | 2022-07-12 | 2024-01-18 | 国立大学法人東京工業大学 | 解析システム、解析装置、解析プログラム、及び解析方法 |
Also Published As
Publication number | Publication date |
---|---|
US20220138937A1 (en) | 2022-05-05 |
JPWO2020166469A1 (ja) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6112173B2 (ja) | 組織染色用蛍光標識体および生体物質検出方法 | |
JP6074427B2 (ja) | 蛍光画像を用いて明視野画像を生成するためのシステム及び方法 | |
JP5906623B2 (ja) | 生体物質発現レベル評価システム | |
WO2013146843A1 (ja) | 医用画像処理装置及びプログラム | |
EP3124969B1 (en) | Biological-material quantitation method based on multiple-antigen immunostaining | |
CN104094116A (zh) | 在哺乳动物个体中检测5t4阳性循环肿瘤细胞的方法和诊断5t4阳性癌症的方法 | |
JP6960224B2 (ja) | 生体物質定量方法、病理診断支援システム及びプログラム | |
JP6911855B2 (ja) | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム | |
KR20220100854A (ko) | 인공 지능 기반 세포 분석을 위한 시스템 및 방법 | |
JP2022513316A (ja) | Pd-1軸指向型治療薬に対する応答を予測するための方法およびシステム | |
JPWO2017126420A1 (ja) | 画像処理装置及びプログラム | |
EP3327427A1 (en) | Target biological substance analysis method and analysis system | |
EP3312606B1 (en) | Pathological specimen, method for producing pathological specimen, and method for acquiring fluorescence image | |
WO2020166469A1 (ja) | 情報提供方法、情報提供装置及びプログラム | |
WO2018143406A1 (ja) | 画像処理装置及びプログラム | |
JP5863057B2 (ja) | 組織評価方法 | |
JP7160047B2 (ja) | 生体物質定量方法、画像処理装置及びプログラム | |
WO2021039592A1 (ja) | 創薬支援方法、創薬支援装置及びプログラム | |
JPWO2019078230A1 (ja) | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム | |
JP6801653B2 (ja) | 画像処理装置、画像処理方法、および画像処理用のプログラム | |
US20210318323A1 (en) | Information Acquiring Method, Information Acquiring Device, and Program | |
WO2022059508A1 (ja) | 生体関連情報取得方法及び生体関連情報取得システム | |
US20230074121A1 (en) | Antibody panel | |
WO2021192910A1 (ja) | 画像生成方法、画像生成装置及びプログラム | |
WO2020262117A1 (ja) | 画像処理システム、画像処理方法及びプログラム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20754977 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020572199 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20754977 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20754977 Country of ref document: EP Kind code of ref document: A1 |